Search Result

Results for "

Acertyl coa carboxilase Inhibitors

" in MCE Product Catalog:

By Targets:	Acetyl-CoA Carboxylase (17) Acyltransferase (29) HMG-CoA Reductase (HMGCR) (71) Stearoyl-CoA Desaturase (SCD) (14) ADC Cytotoxin (2) AMPK (3) Antibiotic (4) Apoptosis (17) ATP Citrate Lyase (1) Autophagy (56) Bacterial (12) Biochemical Assay Reagents (11) Cytochrome P450 (1) Drug Metabolite (19) Endogenous Metabolite (63) ERK (2) Fatty Acid Synthase (FASN) (3) Ferroptosis (15) Flavivirus (1) Fungal (1) Glucosidase (1) HBV (2) Histone Acetyltransferase (3) HIV (2) HIV Protease (1) Influenza Virus (1) Isotope-Labeled Compounds (5) Mitochondrial Metabolism (3) Mitophagy (12) NF-κB (1) Parasite (1) Potassium Channel (8) Reactive Oxygen Species (4) RSV (1) STAT (1) Telomerase (1) Topoisomerase (2) VD/VDR (1)
By Research Areas:	Cancer (65) Cardiovascular Disease (74) Endocrinology (3) Infection (21) Inflammation/Immunology (24) Metabolic Disease (139) Neurological Disease (20)

By Targets:

Acetyl-CoA Carboxylase (17)

Acyltransferase (29)

HMG-CoA Reductase (HMGCR) (71)

Stearoyl-CoA Desaturase (SCD) (14)

ADC Cytotoxin (2)

AMPK (3)

Antibiotic (4)

Apoptosis (17)

ATP Citrate Lyase (1)

Autophagy (56)

Bacterial (12)

Biochemical Assay Reagents (11)

Cytochrome P450 (1)

Drug Metabolite (19)

Endogenous Metabolite (63)

ERK (2)

Fatty Acid Synthase (FASN) (3)

Ferroptosis (15)

Flavivirus (1)

Fungal (1)

Glucosidase (1)

HBV (2)

Histone Acetyltransferase (3)

HIV (2)

HIV Protease (1)

Influenza Virus (1)

Isotope-Labeled Compounds (5)

Mitochondrial Metabolism (3)

Mitophagy (12)

NF-κB (1)

Parasite (1)

Potassium Channel (8)

Reactive Oxygen Species (4)

RSV (1)

STAT (1)

Telomerase (1)

Topoisomerase (2)

VD/VDR (1)

By Research Areas:

Cancer (65)

Cardiovascular Disease (74)

Endocrinology (3)

Infection (21)

Inflammation/Immunology (24)

Metabolic Disease (139)

Neurological Disease (20)

264

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Stearoyl-CoA Desaturase (SCD) HMG-CoA Reductase (HMGCR) Acetyl-CoA Carboxylase Acyltransferase

Cat. No.	Product Name	Target	Research Areas

HY-141540

Lactyl-CoA	Others	Others
Lactyl-CoA is an acyl-CoA formally condensed from the sulfhydryl group of CoA and the carboxyl group of lactic acid, also known as lactyl-CoA. Lactyl-CoA is essential for the biosynthesis of biodegradable and biocompatible lactic acid-based copolymers.

HY-N4301

Monensin B	Others	Others
Monensin B is a polyketide produced by Streptomyces cinnamonensis. Fermentations of Streptomyces cinnamonensis produce a mixture of Monensin A and Monensin B in a ratio dependent upon the relative concentrations of ethylmalonyl-CoA and methylmalonyl-CoA.

HY-126791A

Methylmalonyl coenzyme A tetralithium Methylmalonyl-coa tetralithium	Endogenous Metabolite	Others
Methylmalonyl coenzyme A (Methylmalonyl-CoA) tetralithium is a catabolite of valine, isoleucine, methionine, threonine, odd-chain fatty acids, and cholesterol. Methylmalonyl coenzyme A is converted to succinyl-CoA by enzymatic reaction of methylmalonyl-CoA mutase (MCM) with coenzyme vitamin B12.

HY-N7392

Acetoacetyl-CoA	Biochemical Assay Reagents	Metabolic Disease
Acetoacetyl CoA is the precursor of HMG-CoA in the mevalonate pathway. Acetoacetyl-CoA thiolase catalyzes the reaction to form acetoacetyl-CoA from two acetyl-CoA molecules. Acetoacetyl CoA is essential for cholesterol biosynthesis. Acetoacetyl-CoA is also a intermediate in the biological breakdown and synthesis of fatty acids.

HY-137899

Dephospho-CoA	Endogenous Metabolite	Others
Dephospho-CoA is A direct precursor of Coenzyme A (CoA). Dephospho-CoA kinase (DPCK) catalyzes the ATP-dependent phosphorylation of Dephospho-CoA, the final step in coenzyme A (CoA) biosynthesis.

HY-141466

Crotonyl-CoA	Endogenous Metabolite	Metabolic Disease
Crotonyl-CoA is an intermediate in the fermentation of butyric acid, and in the metabolism of lysine and tryptophan. Crotonyl-CoA is important in the metabolism of fatty acids and amino acids.

HY-142080

Pimeloyl-CoA	Bacterial	Infection
Pimeloyl-CoA is a biotin precursor of Escherichia coli. Pimeloyl-CoA can be used for the research of the pathway of de novo biotin biosynthesis in Escherichia coli.

HY-115899

Malonyl CoA	Endogenous Metabolite Mitochondrial Metabolism	Metabolic Disease
Malonyl CoA is a substrate for fatty acid biosynthesis and an inhibitor of fatty acid oxidation. Malonyl CoA is also a reversible inhibitor of mitochondrial carnitine palmitoyltransferase (CPT) 1.

HY-152117

*Acetyl-CoA* Carboxylase-IN-1**	Acetyl-CoA Carboxylase Bacterial	Infection
Acetyl-CoA Carboxylase-IN-1 is a potent *acetyl-CoA* carboxylase (ACC) inhibitor with an IC₅₀** value of ＜5 nM. Acetyl-CoA Carboxylase-IN-1 has antibacterial activity.

HY-131035

*Lys-CoA* TFA**	Histone Acetyltransferase	Cancer
Lys-CoA TFA is a selective p300 histone acetyltransferase (HAT) inhibitor (IC₅₀=50-500 nM). Lys-CoA TFA displays >100-fold selectivity for p300 over PCAF (IC₅₀=200 μM). Lys-CoA TFA inhibits p300 HAT activity-dependent transcriptional activation.

HY-155668

*HMG-CoA* Reductase-IN-1**	HMG-CoA Reductase (HMGCR)	Metabolic Disease
HMG-CoA Reductase-IN-1 is a *HMG-CoA* reductase** inhibitor. HMG-CoA Reductase-IN-1has high HMGR inhibitory activity and OATP1B1 affinity with pIC₅₀ and pKm values of 8.54 and 1.98, respectively. HMG-CoA Reductase-IN-1 can be used for the research of hypercholesterolemia.

HY-W004784

3-Butynoic acid

Endogenous Metabolite Others

3-Butynoic acid is an inhibitor of acyl CoA dehydrogenase.

3-Butynoic acid	Endogenous Metabolite	Others
3-Butynoic acid is an inhibitor of *acyl CoA* dehydrogenase**.

HY-104032

*Ac-CoA* Synthase Inhibitor1** 2 Publications Verification	RSV	Infection Metabolic Disease
Ac-CoA Synthase Inhibitor1 is a potent, reversible *acetate-dependent acetyl-CoA* synthetase 2 (ACSS2) inhibitor with an IC₅₀** of 0.6 µM. Ac-CoA Synthase Inhibitor1 inhibits the respiratory syncytial virus (RSV).

HY-P2943

Phosphate acetyltransferase	Endogenous Metabolite	Others
Phosphate acetyltransferase is a transferase enzyme, is often used in biochemical studies. Phosphate acetyltransferase catalyzes the reversible transfer of the acetyl group from acetyl-P to CoA forming acetyl-CoA and inorganic phosphate, participating to acetate assimilation/dissimilation reactions.

HY-135024

Phenylacetyl CoA Phenylacetyl Coenzyme A	Endogenous Metabolite	Metabolic Disease
Phenylacetyl CoA is an acceptor oxidoreductase. Phenylacetyl CoA is a membrane-bound molybdenum–iron–sulfur enzyme involved in anaerobic metabolism of phenylalanine in the denitrifying bacterium Thauera aromatica.

HY-131303

Heptadecanoyl Coenzyme A Heptadecanoyl-coa	Biochemical Assay Reagents	Metabolic Disease
Heptadecanoyl Coenzyme A (Heptadecanoyl-CoA), long-chain acyl-coenzymes A (acyl-CoAs) (LCACoA), is an intermediate in lipid metabolism. Heptadecanoyl Coenzyme A can be used for the research of glucose metabolism.

HY-137868

Decanoyl coenzyme A

Decanoyl coa
Endogenous Metabolite Endocrinology

Decanoyl coenzyme A (Decanoyl CoA) is a primer for the fatty acid elongation system in Mycobacterium smegmat.

Decanoyl coenzyme A Decanoyl coa	Endogenous Metabolite	Endocrinology
Decanoyl coenzyme A (Decanoyl CoA) is a primer for the fatty acid elongation system in Mycobacterium smegmat.

HY-138177

Butyryl-Coenzyme A sodium Butyryl coa sodium	Others	Others
Butyryl-Coenzyme A (Butyryl CoA) sodium is a coenzyme A-containing derivative of Butyric acid. Butyryl-Coenzyme A sodium is responsible for the final step of Butyrate production in bacteria.

HY-134423

Stearoyl coenzyme A lithium Stearoyl-coa lithium	Biochemical Assay Reagents	Others
Stearoyl coenzyme A (Stearoyl-CoA) lithium is an active compound that can be used as a substrate for the determination of stearoyl-Coenzyme desaturase in microsomes.

HY-109591A

Oleoyl coenzyme A lithium Oleoyl-coa lithium	Biochemical Assay Reagents	Others
Oleoyl coenzyme A (Oleoyl-CoA) lithium is a thioester of oleic acid and coenzyme A. Oleoyl coenzyme A lithium has a role as an Escherichia coli metabolite and a mouse metabolite.

HY-134422

Isobutyryl coenzyme A lithium Isobutyryl coa lithium	Biochemical Assay Reagents	Others
Isobutyryl coenzyme A (Isobutyryl CoA) lithium is A coenzyme A involved in the metabolic pathway of fatty acids. Isobutyryl coenzyme A lithium is made by combining isobutyric acid (short chain branched fatty acid) with coenzyme A.

HY-134427

Palmitoyl coenzyme A lithium Palmitoyl coa lithium	Endogenous Metabolite	Metabolic Disease
Palmitoyl coenzyme A lithium is an acyl-CoA thioester that can be transported into the mitochondrial matrix via the carnitine shuttle system and is involved in β-oxidation. Palmitoyl coenzyme A lithium can also be used as a substrate for sphingosine biosynthesis.

HY-114293

Acetyl coenzyme A Acetyl-coa	Endogenous Metabolite Autophagy	Metabolic Disease Cardiovascular Disease
Acetyl-coenzyme A (Acetyl-CoA) is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A is also a key precursor of lipid synthesis.

HY-137808

Succinyl-Coenzyme A sodium Succinyl-coa sodium	Endogenous Metabolite	Metabolic Disease Neurological Disease
Succinyl-Coenzyme A (Succinyl-CoA) sodium is an intermediate of the citric acid cycle. Succinyl-Coenzyme A sodium can be converted to succinic acid and can also combines with glycine to form δ-ALA to synthesize porphyrins (heme). Succinyl-Coenzyme A sodium can be used in the study of metabolic, neurological and haematological abnormalities (such as porphyrias) caused by nutritional vitamin B₁₂ deficiency (resulting in a deficiency in Succinyl-Coenzyme A synthesis).

HY-12407

ZK168281	VD/VDR	Metabolic Disease
ZK168281 is a 25-carboxylic ester 1α,25(OH)₂D₃ analog and a pure VDR antagonist with a K_d value of 0.1 nM. ZK168281 is an effective inhibitor of the coactivator (CoA) interaction of its receptor.

HY-113410

3-Methylglutaric acid	Endogenous Metabolite	Metabolic Disease
3-Methylglutaric acid, a leucine metabolite, is a conspicuous C6 dicarboxylic organic acid classically associated with two distinct leucine pathway enzyme deficiencies, 3-hydroxy-3-methylglutaryl CoA lyase (HMGCL) and 3-methylglutaconyl CoA hydratase (AUH).

HY-113596A

Acetyl coenzyme A lithium Acetyl-coa lithium	Endogenous Metabolite Autophagy	Metabolic Disease Cardiovascular Disease
Acetyl-coenzyme A (Acetyl-CoA) lithium is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A lithium, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A lithium is also a key precursor of lipid synthesis.

HY-114293A

Acetyl coenzyme A trilithium Acetyl-coa trilithium	Endogenous Metabolite Autophagy	Metabolic Disease Cardiovascular Disease
Acetyl-coenzyme A (Acetyl-CoA) trilithium is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A trilithium regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A trilithium is also a key precursor of lipid synthesis.

HY-113596

Acetyl Coenzyme A trisodium 1 Publications Verification Acetyl-coa trisodium	Endogenous Metabolite Autophagy	Metabolic Disease
Acetyl-coenzyme A (Acetyl-CoA) trisodium is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A trisodium, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A trisodium is also a key precursor of lipid synthesis.

HY-B0430B

(±)-Pantothenic acid (±)-Pantothenate; (±)-Vitamin B5	Others	Metabolic Disease Neurological Disease
(±)-Pantothenic acid ((±)-Pantothenate), a B-vitamin, is an essential vitamin required for the biosynthesis of coenzyme A (CoA) in mammalian cells. Pantothenic acid has protective activity against valproic acid (VPA)-induced neural tube defects (NTD) in CD-1 mice.

HY-137782

Palmitoleoyl-CoA	Biochemical Assay Reagents	Others
Palmitoleoyl coenzyme A lithium salt is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-N9686

Caffeoyl-CoA

Others Others

Caffeoyl-CoAcould be isolated from leaf tissues of Gramineae with a K_m value of 1.45 μM.

Caffeoyl-CoA	Others	Others
Caffeoyl-CoAcould be isolated from leaf tissues of Gramineae with a K_m value of 1.45 μM.

HY-130755

Cyclohexanoyl coenzyme A CHcoa; Cyclohexanecarboxyl-coa; Cyclohexanoyl coa	Others	Others
Cyclohexanoyl coenzyme A is the active form of cyclohexane carboxylic acid (CHC) from anaerobic degradation in Rhodopseudomonas palustris.

HY-126050

(R)-Pantetheine Pantetheine	Endogenous Metabolite	Metabolic Disease
(R)-Pantetheine is the biosynthetic precursor to *CoA. (R)-Pantetheine and its corresponding disulfide pantethine, play a key role in metabolism as a building block of coenzyme A (CoA).*

HY-W017522

Adipic acid	Endogenous Metabolite	Metabolic Disease
Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism.

HY-112540

Acetoacetic acid	Endogenous Metabolite	Neurological Disease Metabolic Disease
Acetoacetic acid is an endogenous metabolite present in Cerebrospinal_Fluid and Blood that can be used for the research of Meningitis, Pregnancy, 3 Hydroxy 3 Methylglutaryl CoA Lyase Deficiency, Preeclampsia/Eclampsia, Diabetes Mellitus Type 2, Glucose Transporter Type 1 Deficiency Syndrome and Succinyl CoA:3 Oxoacid CoA Transferase Deficiency.

HY-W017522S3

Adipic acid-13C	Endogenous Metabolite	Metabolic Disease
Adipic acid-¹³C is the ¹³C labeled Adipic acid[1]. Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism[2].

HY-W017522S

Adipic acid-d10	Endogenous Metabolite	Metabolic Disease
Adipic acid-d₁₀ is the deuterium labeled Adipic acid[1]. Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism[2].

HY-W017522S2

Adipic acid-d4	Endogenous Metabolite	Metabolic Disease
Adipic acid-d₄ is the deuterium labeled Adipic acid[1]. Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism[2].

HY-W017522S1

Adipic acid-13C6	Endogenous Metabolite	Metabolic Disease
Adipic acid-¹³C₆ is the ¹³C labeled Adipic acid[1]. Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism[2].

HY-W017522S4

Adipic acid-d8	Endogenous Metabolite	Metabolic Disease
Adipic acid-d₈ is the deuterium labeled Adipic acid[1]. Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism[2].

HY-15823

CAY10566 5+ Cited Publications	Stearoyl-CoA Desaturase (SCD)	Cancer
CAY10566 is a potent, orally bioavailable and selective *stearoyl-CoA* desaturase1 (SCD1) inhibitor with IC₅₀*s of 4.5 and 26 nM in mouse and human enzymatic assays, respectively. CAY10566 also shows excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs* (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells (IC₅₀=7.9 nM or 6.8 nM).

HY-W017522S5

Adipic acid-d4-1	Endogenous Metabolite	Metabolic Disease
Adipic acid-d₄-1 is the deuterium labeled Adipic acid[1]. Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism[2].

HY-141474

Glutaryl coenzyme A lithium	Biochemical Assay Reagents	Others
Glutaryl coenzyme A lithium is a Glutaryl coenzyme A derivative. Glutaryl coenzyme A is an important endogenous metabolites. Glutaryl coenzyme A lithium can be used in HMG-CoA or Glutaryl-CoA related experiment.

HY-32219

T863 5+ Cited Publications	Acyltransferase	Metabolic Disease
T863 is an orally active, selective and potent *DGAT1 (Acyl-CoA:diacylglycerol acyltransferase 1)* inhibitor that interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells.

HY-117581

L-669,262 6-Oxo Simvastatin; Iso-simvastatin-6-one	HMG-CoA Reductase (HMGCR)	Metabolic Disease
L-669,262, a potent inhibitor of *3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, with an IC₅₀* of 0.10 ng/mL for rat liver HMG-CoA.

HY-15259

CP-640186 5+ Cited Publications	Acetyl-CoA Carboxylase	Metabolic Disease
CP-640186 is an orally active and cell-permeable *Acetyl-CoA* carboxylase (ACC) inhibitor with IC₅₀*s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively. Acetyl-CoA* carboxylase (ACC) is a key enzyme of fatty acid metabolism that enables the synthesis of malonyl-CoA. CP-640186 can also stimulate muscle fatty acid oxidation.

HY-15259A

CP-640186 hydrochloride 5+ Cited Publications	Acetyl-CoA Carboxylase	Metabolic Disease
CP-640186 hydrochloride is an orally active and cell-permeable *Acetyl-CoA* carboxylase (ACC) inhibitor with IC₅₀*s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively. Acetyl-CoA* carboxylase (ACC) is a key enzyme of fatty acid metabolism that enables the synthesis of malonyl-CoA. CP-640186 hydrochloride can also stimulate muscle fatty acid oxidation.

HY-116037A

trans-10-Heptadecenoic acid	Others	Others
trans-10-Heptadecenoic acid is a trans-fatty acid. trans-10-Heptadecenoic acid synthesizes polyhydroxy-chain alkanoates under the action of 2, 4-dienyl-CoA reductase and Delta3, Delta2-enyl-CoA isomerase. In the absence of 2, 4-dienyl-CoA reductase, trans-10-Heptadecenoic acid is degraded by enyl-CoA hydratase II of the multifunctional enzyme (MFE). trans-10-Heptadecenoic acid leads to massive intracellular carbon outflow through reductase dependent and direct MFE dependent pathways.

HY-135383B

(Z)-Pitavastatin calcium	Others	Metabolic Disease
(Z)-Pitavastatin calcium is the Z-Isomer of Pitavastatin hemicacium. Pitavastatin calcium is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin calcium inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells.

HY-113165

Isobutyryl-L-carnitine

Endogenous Metabolite Metabolic Disease

Isobutyryl-L-carnitine is a product of the acyl-CoA dehydrogenases.
HY-113165A

Isobutyryl-L-carnitine chloride

Endogenous Metabolite Metabolic Disease

Isobutyryl-L-carnitine chloride is a product of the acyl-CoA dehydrogenases.
HY-13528

Clinofibrate

S-8527
HMG-CoA Reductase (HMGCR) Autophagy Metabolic Disease

Clinofibrate (S-8527) is a hypelipidemic agent and a HMG-CoA reductase inhibitor.

HY-17502

Simvastatin 30+ Cited Publications MK 733	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis Ferroptosis	Cardiovascular Disease Cancer
Simvastatin (MK 733) is a competitive inhibitor of *HMG-CoA* reductase with a K_i** of 0.2 nM.

HY-104051

Monacolin J Antibiotic MB 530A; Lovastatin diol lactone	HMG-CoA Reductase (HMGCR) Autophagy	Metabolic Disease
Monacolin J is an inhibitor of cholesterol biosynthesis, and inhibits the activity of *HMG-CoA* reductase**.

HY-N0504

Lovastatin 15+ Cited Publications Mevinolin	HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis	Cardiovascular Disease Cancer
Lovastatin is a cell-permeable *HMG-CoA* reductase** inhibitor used to lower cholesterol.

HY-N2923

β-Amyrin acetate	HMG-CoA Reductase (HMGCR) Fungal	Infection Metabolic Disease Inflammation/Immunology Cardiovascular Disease
β-Amyrin acetate is a triterpenoid with potent anti-inflammatory, antifungal, anti-diabetic, anti-hyperlipidemic activities. β-Amyrin acetate can inhibit *HMG-CoA* reductase activity by locating in the hydrophobic binding cleft of HMG CoA reductase.

HY-117262

Propaquizafop

Acetyl-CoA Carboxylase Others

Propaquizafop is a phenoxyisopropionic acid herbicide and an acetyl-coA carboxylase inhibitor.

HY-139134

S-2E	HMG-CoA Reductase (HMGCR) Acetyl-CoA Carboxylase	Cardiovascular Disease
S-2E is an orally active and noncompetitive *HMG-CoA* reductase and acetyl-CoA carboxylase** inhibitor. S-2E has an anti-hyperlipidemic action. S-2E has the potential for familial hypercholesterolemia and mixed hyperlipidemia research.

HY-34740

Ethylmalonic acid	Endogenous Metabolite	Metabolic Disease Neurological Disease
Ethylmalonic acid is non-carcinogenic potentially toxic and associated with anorexia nervosa and malonyl-CoA decarboxylase deficiency.

HY-B0144AS

Pitavastatin D4 NK-104 d₄	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cancer Metabolic Disease
Pitavastatin-d₄ is deuterium labeled Pitavastatin. Pitavastatin is a potent HMG-CoA reductase inhibitor.

HY-135384

tert-Buthyl Pitavastatin

Drug Metabolite Cardiovascular Disease

tert-Buthyl Pitavastatin is the metabolite of Pitavastatin. Pitavastatin is a potent HMG-CoA reductase inhibitor.

HY-W015300

Suberic acid Octanedioic acid	Endogenous Metabolite	Metabolic Disease
Suberic acid (Octanedioic acid) is found to be associated with carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency.

HY-N7347

(-)-Hydroxycitric acid lactone Garcinia lactone	ATP Citrate Lyase	Metabolic Disease
(-)-Hydroxycitric acid lactone (Garcinia lactone) is an anti-obesity agent and a popular weight loss food supplement. (-)-Hydroxycitric acid lactone is a potent inhibitor of ATP-citrate lyase. (-)-Hydroxycitric acid lactone catalyzes the extramitochondrial cleavage of citrate to oxaloacetate and acetyl-CoA, limits the availability of acetyl-CoA units required for fatty acid synthesis.

HY-15700

PluriSIn 1 2 Publications Verification NSC 14613	Stearoyl-CoA Desaturase (SCD) Apoptosis	Cancer
PluriSIn 1 (NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD), and is a pluripotent cell-specific inhibitor.

HY-135404

Anhydrosimvastatin Dehydro simvastatin	Drug Metabolite	Cardiovascular Disease Cancer
Anhydrosimvastatin (Impurity C) is an impurity of Simvastatin. Simvastatin is a competitive inhibitor of HMG-CoA reductase.

HY-123672

Lovastatin hydroxy acid sodium Mevinolinic acid sodium	HMG-CoA Reductase (HMGCR)	Metabolic Disease
Lovastatin hydroxy acid sodium (Mevinolinic acid sodium) is a highly potent inhibitor of HMG-CoA reductase with a K_i of 0.6 nM.

HY-135402

2'-Ethyl Simvastatin

HMG-CoA Reductase (HMGCR) Cancer Cardiovascular Disease

2'-Ethyl Simvastatin (compound 6) is a Mevinolin analog, with HMG-CoA reductase inhibition.

HY-113408

Tiglyl carnitine 1 Publications Verification	Endogenous Metabolite	Metabolic Disease
Tiglyl carnitine is found to be associated with celiac disease and mitochondrial acetoacetyl-CoA thiolase (T2) deficiency.

HY-W015444

2-Hydroxyoctanoic acid

Endogenous Metabolite Metabolic Disease

2-Hydroxyoctanoic acid is a medium chain acyl-CoA synthetase inhibitor with a K_i of 500 μM.

HY-B0144AS1

Pitavastatin-d5 sodium NK-104-d₅ sodium	Mitophagy HMG-CoA Reductase (HMGCR) Apoptosis Autophagy	Cancer Metabolic Disease
Pitavastatin-d₅ (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.

HY-111417

GSK2973980A

Acyltransferase Metabolic Disease

GSK2973980A is a potent and selective Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitor with an IC₅₀ of 3 nM.
HY-B2007

Fluazifop-P-butyl

Acetyl-CoA Carboxylase Metabolic Disease

Fluazifop-P-butyl, a graminicide from arylophenoxypropionate group, is a acetyl-CoA carboxylase (ACCase) inhibitor.

HY-B0165A

Pravastatin sodium 4 Publications Verification CS-514 sodium	HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis	Cardiovascular Disease Cancer
Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC₅₀ of 5.6 μM.

HY-101068

TOFA

5 Publications Verification

RMI14514; MDL14514
Acetyl-CoA Carboxylase Cancer

TOFA (RMI14514;MDL14514) is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA ).

HY-122439

Lovastatin acid Mevinolinic acid; MSD803	HMG-CoA Reductase (HMGCR) Drug Metabolite	Cancer Cardiovascular Disease
Lovastatin acid (Mevinolinic acid), an active metabolite of Lovastatin, is a potent competitive *HMG-CoA* reductase inhibitor with a K_i** of 0.6 nM.

HY-19183

E-5324

Acyltransferase Metabolic Disease

E-5324 is potent inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT) with IC₅₀s of 44 to 190 nM.

HY-135405

4-Acetylsimvastatin	Others	Cardiovascular Disease Cancer
4-Acetylsimvastatin is an acetylated simvastatin. Simvastatin is a competitive inhibitor of HMG-CoA reductase with a K_i of 0.2 nM.

HY-W014787

Decanedioic acid	Endogenous Metabolite	Metabolic Disease
Decanedioic acid, a normal urinary acid, is found to be associated with carnitine-acylcarnitine translocase deficiency and medium chain acyl-CoA dehydrogenase deficiency.

HY-101627

YM17E

Acyltransferase Metabolic Disease

YM17E is an inhibitor of acyl CoA:cholesterol acyltransferase (ACAT), with IC₅₀ of 44 nM in rabbit liver microsomes in vitro.
HY-N10234

Phenylpyropene A

Acyltransferase Infection

Phenylpyropene A, a fungal metabolite, is a potent acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor with an IC₅₀ of 0.8 μM.

HY-N0504S1

Lovastatin-d9	HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis	Cardiovascular Disease Cancer
Lovastatin-d₉ is the deuterium labeled Lovastatin. Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.

HY-N0504S2

Lovastatin-d3 Mevinolin-d₃	HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis	Cardiovascular Disease Cancer
Lovastatin-d₃ is deuterium labeled Lovastatin. Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.

HY-16281

Lecimibide DuP 128	Acyltransferase	Metabolic Disease
Lecimibide (DuP 128) is a potent and specific acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor for antihyperlipidemia research.

HY-16901A

Firsocostat (S enantiomer) ND-630 (S enantiomer); GS-0976 (S enantiomer); NDI-010976 (S enantiomer)	Acetyl-CoA Carboxylase	Others
Firsocostat S enantiomer (ND-630 S enantiomer) is the less active S enantiomer of Firsocostat. Firsocostat is an acetyl-CoA carboxylase (ACC) inhibitor.

HY-136347

3α-Hydroxy pravastatin sodium	HMG-CoA Reductase (HMGCR) Drug Metabolite	Cardiovascular Disease
3α-Hydroxy pravastatin sodium is the major metabolite of Pravastatin. Pravastatin is a competitive HMG-CoA reductase inhibitor.

HY-114294A

DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium	Biochemical Assay Reagents	Metabolic Disease
DL-3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) disodium is a disodium salt compound of HMG-CoA, is a intermediate of terpenes and ketone bodies. DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium also involves in ester metabolism in vivo, as a precursor for cholesterol synthesis, and regulates cholesterol synthesis by coupling LDL receptor.

HY-139451

ELOVL6-IN-3	Others	Neurological Disease
ELOVL6-IN-1 is a potent, orally active and selective ELOVL6 inhibitor. ELOVL6-IN-1 dose-dependently inhibits mouse ELOVL6 activities, with an IC₅₀ value of 0.350 μM. ELOVL6-IN-1 inhibits ELOVL6 in a noncompetitive manner for malonyl-CoA (K_i=994 nM) and palmitoyl-CoA.

HY-N10224

Terpendole C	Acyltransferase	Metabolic Disease
Terpendole C, produced by Albophoma yamanashiensis, shows potent inhibitory activity against acyl-CoA: cholesterol acyltransferase (ACAT).

HY-N8331

Terpendole I

Acyltransferase Endogenous Metabolite Cancer

Terpendole I, a fungal indoloditerpene, is a ACAT (acyl-CoA: cholesterol acyltransferase) inhibitor (IC₅₀=145 µM).
HY-135383A

(3S,5R)-Pitavastatin calcium

Others Metabolic Disease

(3S,5R)-Pitavastatin cacium is the enantiomer of Pitavastatin. Pitavastatin is a potent HMG-CoA reductase inhibitor.

HY-113165AS

Isobutyryl-L-carnitine-d3 chloride	Endogenous Metabolite	Metabolic Disease
Isobutyryl-L-carnitine-d₃ (chloride) is the deuterium labeled Isobutyryl-L-carnitine chloride. Isobutyryl-L-carnitine chloride is a product of the acyl-CoA dehydrogenases[1].

HY-Y0068

N-Acetyl-L-phenylalanine 1 Publications Verification N-Acetylphenylalanine	Endogenous Metabolite	Others
N-Acetyl-L-phenylalanine (N-Acetylphenylalanine), the principal acylamino acid in Escherichia coli, is synthesized from L-phenylalanine and acetyl-CoA.

HY-107709

MK-4074 3 Publications Verification	Acetyl-CoA Carboxylase	Metabolic Disease
MK-4074 is a liver-specific inhibitor of *acetyl-CoA* carboxylase ACC1 and ACC2 with IC₅₀** values of approximately 3 nM.

HY-128828

2-Hydroxy atorvastatin calcium salt	Drug Metabolite	Metabolic Disease
2-Hydroxy atorvastatin calcium salt is a hydroxy metabolite of Atorvastatin calcium salt. Atorvastatin is a potent HMG-CoA reductase inhibitor with an IC₅₀ value of 8 nM.

HY-B0165

Pravastatin CS-514	Autophagy HMG-CoA Reductase (HMGCR)	Cardiovascular Disease Cancer
Pravastatin (CS-514) is a competitive *HMG-CoA* reductase** inhibitor against sterol synthesis with IC₅₀ of 5.6 μM.

HY-125643

Pitavastatin lactone	Drug Metabolite	Cardiovascular Disease
Pitavastatin lactone is a major metabolite of Pitavastatin in humans. Pitavastatin is a potent competitive inhibitor of HMG-CoA reductase little metabolized in hepatic microsomes.

HY-U00430

MGAT2-IN-2

Acyltransferase Metabolic Disease

MGAT2-IN-2 is a potent and selective acyl CoA:monoacylglycerol acyltransferase 2 (MGAT2) inhibitor with an IC₅₀ of 3.4 nM.
HY-112812

SCD1 inhibitor-1

Stearoyl-CoA Desaturase (SCD) Cancer Metabolic Disease

SCD1 inhibitor-1 is a potent and liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitor.

HY-136344

Simvastatin Acyl-β-D-glucuronide	Drug Metabolite	Others
Simvastatin Acyl-β-D-glucuronide is a metabolite of Simvastatin. Simvastatin is a competitive inhibitor of HMG-CoA reductase with a K_i of 0.2 nM.

HY-16943

Moiramide B	Bacterial Acetyl-CoA Carboxylase	Infection
Moiramide B is a potent *acetyl-CoA* carboxylase (ACC) inhibitor with an IC₅₀** value of 6 nM. Moiramide B has antibacterial activity.

HY-113410S

3-Methylglutaric acid-d4	Endogenous Metabolite	Metabolic Disease
3-Methylglutaric acid-d₄ is the deuterium labeled 3-Methylglutaric acid[1]. 3-Methylglutaric acid, a leucine metabolite, is a conspicuous C6 dicarboxylic organic acid classically associated with two distinct leucine pathway enzyme deficiencies, 3-hydroxy-3-methylglutaryl CoA lyase (HMGCL) and 3-methylglutaconyl CoA hydratase (AUH)[2][3].

HY-B0144A

Pitavastatin NK-104	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cancer Metabolic Disease Neurological Disease Cardiovascular Disease
Pitavastatin (NK-104) is a potent *hydroxymethylglutaryl-CoA* (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC₅₀** of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects.

HY-B0144B

Pitavastatin sodium NK-104 sodium	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cancer Metabolic Disease Neurological Disease Cardiovascular Disease
Pitavastatin (NK-104) sodium is a potent *hydroxymethylglutaryl-CoA* (HMG-CoA) reductase inhibitor. Pitavastatin sodium inhibits cholesterol synthesis from acetic acid with an IC₅₀** of 5.8 nM in HepG2 cells. Pitavastatin sodium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin sodium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects.

HY-126455

Penicillide Vermixocin A	Acyltransferase	Metabolic Disease
Penicillide (Vermixocin A), isolated from Talaromyces derxii cultivated on rice, shows inhibitory activity against acyl-CoA:cholesterol acyltransferase (ACAT).

HY-N0504R

Lovastatin (Standard) Mevinolin (Standard)	HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis	Cardiovascular Disease Cancer
Lovastatin (Standard) is the analytical standard of Lovastatin. This product is intended for research and analytical applications. Lovastatin is a cell-permeable *HMG-CoA* reductase** inhibitor used to lower cholesterol.

HY-122078

FR-190809

Acyltransferase Metabolic Disease

FR-190809 is a potent, nonadrenotoxic, orally efficacious acyl-CoA:cholesterol O-acyltransferase (ACAT) inhibitor, with an IC₅₀ of 45 nM.

HY-109033

Fosmetpantotenate RE-024	Others	Neurological Disease
Fosmetpantotenate is a phosphopantothenic acid (PPA) precursor designed to release PPA intracellularly, leading to restoration of CoA levels. Fosmetpantotenate is used to research pantothenate kinase-associated neurodegeneration.

HY-136345

(Rac)-3′-Hydroxy simvastatin	Drug Metabolite	Others
(Rac)-3′-Hydroxy simvastatin is a metabolite of Simvastatin. Simvastatin is a competitive inhibitor of HMG-CoA reductase with a K_i of 0.2 nM.

HY-14664AS

Fluvastatin-d6 sodium XU 62-320-d₆	HMG-CoA Reductase (HMGCR) Autophagy	Cardiovascular Disease Cancer
Fluvastatin-d₆ (sodium) is deuterium labeled Fluvastatin sodium. Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM.

HY-113024

Pristanic acid	Endogenous Metabolite	Metabolic Disease
Pristanic acid is an endogenous metabolite present in Blood that can be used for the research of Alpha Methylacyl CoA Racemase Deficiency and Zellweger Syndrome.

HY-109591

Oleoyl Coenzyme A	Biochemical Assay Reagents	Others
Oleoyl coenzyme A (Oleoyl-CoA) is a thioester of oleic acid and coenzyme A. Oleoyl coenzyme A has a role as an Escherichia coli metabolite and a mouse metabolite.

HY-112790

Adenosylcobalamin Coenzyme B12; Cobamamide; AdoCbl	Endogenous Metabolite	Metabolic Disease
Adenosylcobalamin (Coenzyme B12;Cobamamide;AdoCbl) is an active form of Vitamin B₁₂ which is a cofactor for methylmalonyl CoA mutase

HY-100400A

K-604 dihydrochloride	Acyltransferase	Cardiovascular Disease
K-604 dihydrochloride is a potent and selective acyl-CoA:cholesterol acyltransferase 1 (ACAT-1) inhibitor with an IC₅₀ of 0.45±0.06 μM.

HY-135383

(3S,5S)-Pitavastatin calcium

Others Metabolic Disease

(3S,5S)-Pitavastatin cacium is the 3-epimer of Pitavastatin. Pitavastatin is a potent HMG-CoA reductase inhibitor.

HY-17502S

Simvastatin-d11 MK 733-d₁₁	Isotope-Labeled Compounds Mitophagy HMG-CoA Reductase (HMGCR) Ferroptosis Autophagy Apoptosis	Cancer Cardiovascular Disease
Simvastatin-d₁₁ is the deuterium labeled Simvastatin. Simvastatin (MK 733) is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM[1][2].

HY-34740S

Ethylmalonic acid-d3	Endogenous Metabolite	Metabolic Disease Neurological Disease
Ethylmalonic acid-d₃ is the deuterium labeled Ethylmalonic acid. Ethylmalonic acid is non-carcinogenic potentially toxic and associated with anorexia nervosa and malonyl-CoA decarboxylase deficiency.

HY-15822

MF-438 2 Publications Verification	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
MF-438 is a potent and orally bioavailable *stearoyl-CoA* desaturase 1 (SCD1) inhibitor with an IC₅₀** of 2.3 nM for rSCD1.

HY-113166

Dodecanoylcarnitine	Endogenous Metabolite	Metabolic Disease
Dodecanoylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I/II deficiency, and is also associated with celiac disease.

HY-34740S1

Ethylmalonic acid-d5	Endogenous Metabolite	Metabolic Disease Neurological Disease
Ethylmalonic acid-d₅ is the deuterium labeled Ethylmalonic acid. Ethylmalonic acid is non-carcinogenic potentially toxic and associated with anorexia nervosa and malonyl-CoA decarboxylase deficiency.

HY-B0144S

Pitavastatin-d4 hemicalcium NK-104-d₄ (hemicalcium); Pitavastatin-d₄ (hemicalcium)	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Metabolic Disease Cancer
Pitavastatin-d₄ (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].

HY-19762

GSK1940029 2 Publications Verification SCD inhibitor 1	Stearoyl-CoA Desaturase (SCD)	Cancer
GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase (SCD) inhibitor extracted from patent WO/2009060053 A1, compound example 16.

HY-101873

Atorvastatin lactone	HMG-CoA Reductase (HMGCR)	Metabolic Disease Inflammation/Immunology
Atorvastatin lactone is a proagent form of atorvastatin. Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.

HY-50709

A939572 25+ Cited Publications	Stearoyl-CoA Desaturase (SCD)	Cancer
A939572 is a potent, and orally bioavailable *stearoyl-CoA* desaturase1 (SCD1) inhibitor with IC₅₀ values of <4 nM and 37 nM for mSCD1 and hSCD1**, respectively.

HY-N2924

β-Amyrin palmitate	HMG-CoA Reductase (HMGCR)	Cardiovascular Disease Endocrinology
β-Amyrin palmitate shows HMG-CoA* reductase* inhibition. And β-Amyrin palmitate has anti-diabetes mellitus activity.

HY-100249

XEN723	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of *Stearoyl-CoA* Desaturase (SCD1) with IC₅₀**s of 45 and 524 nM in mouse and HepG2 cell, respectively.

HY-121795

Pravastatin lactone	HMG-CoA Reductase (HMGCR)	Cardiovascular Disease
Pravastatin lactone is a potent *HMG-CoA* inhibitor. Pravastatin Lactone is a metabolite of pravastatin. Pravastatin lactone reduces blood cholesterol levels by inhibiting cholesterol synthesis.

HY-17502S1

Simvastatin-d3 MK 733-d₃	Apoptosis Autophagy HMG-CoA Reductase (HMGCR) Ferroptosis Mitophagy
Simvastatin-d₃ is the deuterium labeled Simvastatin[1]. Simvastatin (MK 733) is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM[2].

HY-108774

Rosuvastatin zinc salt Rosuvastatin zinc	Others	Metabolic Disease Cardiovascular Disease
Rosuvastatin zinc salt (Rosuvastatin zinc) is a zinc-containing form of Rosuvastatin (HY-17504A). Rosuvastatin is a *HMG-CoA* reductase** inhibitor and can be used for atherosclerosis research.

HY-N6739

Beauvericin	Acyltransferase	Infection Cardiovascular Disease
Beauvericin is a Fusarium mycotoxin. Beauvericin inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC₅₀ of 3 μM in an enzyme assay using rat liver microsomes.

HY-123672S

Lovastatin-d3 hydroxy acid sodium	HMG-CoA Reductase (HMGCR)	Metabolic Disease
Lovastatin-d₃ hydroxy acid (sodium) is the deuterium labeled Lovastatin hydroxy acid sodium. Lovastatin hydroxy acid sodium (Mevinolinic acid sodium) is a highly potent inhibitor of HMG-CoA reductase with a Ki of 0.6 nM[1].

HY-110231

Simvastatin-d6 MK 733-d6	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis Ferroptosis	Cardiovascular Disease Cancer
Simvastatin-d6 (MK 733-d6) is the deuterium labeled Simvastatin. Simvastatin (MK 733) is a competitive inhibitor of *HMG-CoA* reductase with a K_i** of 0.2 nM.

HY-N9524

Ilexoside XLVIII	Acyltransferase	Metabolic Disease
Ilexoside XLVIII is an acyl CoA cholesteryl acyl transferase (ACAT) inhibitor. Ilexoside XLVIII is a triterpene saponin isolated from an aqueous extract of the leaves of Ilex kudincha.

HY-113347

cis-5-Tetradecenoic acid	Endogenous Metabolite	Others
cis-5-Tetradecenoic acid is an endogenous metabolite present in Blood that can be used for the research of Long Chain 3 Hydroxyacyl CoA Dehydrogenase Deficiency.

HY-136346

2-Hydroxy atorvastatin lactone	Drug Metabolite	Cardiovascular Disease
2-Hydroxy atorvastatin lactone is a metabolite of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids.

HY-N6702

Enniatin A	Acyltransferase	Infection Cardiovascular Disease
Enniatin A is a Fusarium mycotoxin. Enniatin A inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC₅₀ of 22 μM in an enzyme assay using rat liver microsomes.

HY-B0144

Pitavastatin Calcium 4 Publications Verification NK-104 hemicalcium; Pitavastatin hemicalcium	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cancer Metabolic Disease Neurological Disease Cardiovascular Disease
Pitavastatin Calcium (NK-104 hemicalcium) is a potent *hydroxymethylglutaryl-CoA* (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC₅₀** of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects.

HY-134426

DL-β-Hydroxybutyryl coenzyme A lithium	Endogenous Metabolite	Metabolic Disease
DL-β-Hydroxybutyryl coenzyme A lithium is an intermediate in the fermentation of butyric acid and the metabolism of lysine and tryptophan, and is produced from β-hydroxybutyric acid by short-chain-CoA synthase.

HY-11034

CVT-12012	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
CVT-12012 is a potent and orally bioavailable stearoyl-coA desaturase (SCD) inhibitor, with IC₅₀s of 38 nM, 6.1 nM for rat microsomal and human HEPG2, respectively.

HY-135381

3-Oxo Atorvastatin	Drug Metabolite	Cardiovascular Disease
3-Oxo Atorvastatin is an impurity of 3-Oxo Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids.

HY-B1189

Meglutol Dicrotalic acid; 3-Hydroxy-3-methylglutaric acid	HMG-CoA Reductase (HMGCR) Autophagy Endogenous Metabolite	Cardiovascular Disease
Meglutol is an antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids, and inhibits the activity of hydroxymethylglutarryl CoA reductases, which is the rate limiting enzyme in the biosynthesis of cholesterol.

HY-Y1125

6-Methyluracil Pseudothymine	Endogenous Metabolite	Metabolic Disease
6-Methyluracil (Pseudothymine), a metabolite of Uracil, can be used as an indicator of acetoacetyl-CoA (AACoA) accumulation. 6-Methyluracil exhibits antiradiation effect in vivo.

HY-P2887

Acetate kinase (ACK)	Endogenous Metabolite	Others
Acetate kinase (ACK) is an enzyme widely distributed in bacteria and archaea. In the presence of ATP and divalent cations, it catalyzes the phosphorylation of acetate and promotes the production of acetyl-CoA. Often used in biochemical research.

HY-101842

ND-646 5+ Cited Publications	Acetyl-CoA Carboxylase	Cancer
ND-646 is an orally bioavailable and steric inhibitor of acetyl-CoA carboxylase (ACC) with IC₅₀s of 3.5 nM and 4.1 nM for recombinant hACC1 and hACC2, respectively.

HY-B0165AR

Pravastatin sodium (Standard) CS-514 sodium (Standard)	HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis	Cardiovascular Disease Cancer
Pravastatin (sodium) (Standard) is the analytical standard of Pravastatin (sodium). This product is intended for research and analytical applications. Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC₅₀ of 5.6 μM.

HY-135380

Atorvastatin acetonide tert-butyl ester	Others	Cardiovascular Disease
Atorvastatin acetonide tert-butyl ester is a useful pharmaceutical intermediate in the preparation of Atorvastatin salts. Atorvastatin is an orally active HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids.

HY-W015300S

Suberic acid-d4 Octanedioic acid-d₄	Endogenous Metabolite	Metabolic Disease
Suberic acid-d₄ is the deuterium labeled Suberic acid[1]. Suberic acid (Octanedioic acid) is found to be associated with carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency[2].

HY-117430

Hymeglusin F-244; 1233A; L-659699	Flavivirus Antibiotic	Cancer Infection Metabolic Disease
Hymeglusin, as a fungal β-lactone antibiotic, is a *HMG-CoA* synthase inhibitor (IC₅₀ = 0.12 μM). Hymeglusin covalently modifies the active Cys¹²⁹ residue of the enzyme.

HY-W009993

3,4-Methylenedioxycinnamic acid	Others	Others
3,4-Methylenedioxycinnamic acid is an inhibitor of the *phenylpropanoid enzyme 4-hydroxycinnamoyl-CoA* ligase**. 3,4-Methylenedioxycinnamic acid increases the formation of soluble phenolics in particular of vanillic acid.

HY-B0165CS

Pravastatin-d3 sodium salt	HMG-CoA Reductase (HMGCR) Autophagy	Cardiovascular Disease
Pravastatin-d₃ (sodium) is the deuterium labeled Pravastatin sodium salt. Pravastatin (CS-514) sodium salt is a competitive HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM[1][2].

HY-126852

4-Hydroxy Atorvastatin lactone P-Hydroxyatorvastatin lactone; 4-ATL	Drug Metabolite	Metabolic Disease Inflammation/Immunology
4-Hydroxy Atorvastatin lactone is a metabolite of Atorvastatin (HY-B0589). Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids.

HY-W015300S1

Suberic acid-d12 Octanedioic acid-d₁₂	Endogenous Metabolite	Metabolic Disease
Suberic acid-d₁₂ is the deuterium labeled Suberic acid[1]. Suberic acid (Octanedioic acid) is found to be associated with carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency[2].

HY-B0165AS

Pravastatin-13C,d3 sodium CS-514-¹³C,d₃ (sodium)	HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis	Cardiovascular Disease Cancer
Pravastatin-¹³C,d₃ (sodium) is the ¹³C- and deuterium labeled Pravastatin (sodium). Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.

HY-135379

Atorvastatin acetonide	Drug Metabolite	Cardiovascular Disease
Atorvastatin acetonide is an impurity of Atorvastatin, and extracted from patent WO2011131605A1, Compound 4. Atorvastatin is an orally active HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids.

HY-17640

Nicodicosapent	Fatty Acid Synthase (FASN) Autophagy	Metabolic Disease
Nicodicosapent is a fatty acid niacin conjugate that is also an inhibitor of the sterol regulatory element binding protein (SREBP), a key regulator of cholesterol metabolism proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase, and NPC1L1.

HY-N11637

Ganoderenic acid K	HMG-CoA Reductase (HMGCR)	Inflammation/Immunology
Ganoderenic acid K is a natural product, that can be isolated from fruiting bodies of Ganoderma lucidum. Ganoderenic acid K shows strong inhibitory activity against *HMG-CoA* reductase (HMGCR) with IC₅₀** of 16.5 μM.

HY-114316

HMG499	HMG-CoA Reductase (HMGCR) Autophagy	Metabolic Disease Cardiovascular Disease
HMG499 is a potent and selective *HMG-CoA* reductase inhibitor with an IC₅₀** of 0.41 μM. HMG499 can prevent statins-induced accumulation of HMGCR, reduce serum cholesterol levels and decrease atherosclerosis.

HY-N10076

Ganomycin I	HMG-CoA Reductase (HMGCR) Glucosidase HIV Protease	Infection Metabolic Disease
Ganomycin I is a dual inhibitor of α-Glucosidase and *HMG-CoA* reductase. Ganomycin I can also inhibits HIV protease**. Ganomycin I exhibits anti-diabetic and anti-osteoclastogenesis effects.

HY-113067

Phytanic acid	Endogenous Metabolite	Metabolic Disease
Phytanic acid is an endogenous metabolite present in Blood that can be used for the research of Zellweger Syndrome, Alpha Methylacyl CoA Racemase Deficiency, Rhizomelic Chondrodysplasia Punctata and Infantile Refsum Disease.

HY-W020033S

Lanosterol-d6	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease
Lanosterol-d₆ is deuterium labeled Lanosterol. Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol s

HY-135358

(Rac)-5-Keto Fluvastatin 3-Hydroxy-5-Keto Fluvastatin	HMG-CoA Reductase (HMGCR)	Cardiovascular Disease
(Rac)-5-Keto Fluvastatin (3-Hydroxy-5-Keto Fluvastatin) is an impurity of Fluvastatin (XU 62320). Fluvastatin is a HMG-CoA reductase inhibitor with an IC₅₀ of 8 nM.

HY-155033

SSI-4	Stearoyl-CoA Desaturase (SCD)	Others
SSI-4 is an inhibitor of Stearoyl CoA desaturase 1 (SCD1) , which can be modified with ¹¹C, used as a ligand to in vivo small animal PET/CT imaging of SCD1.

HY-136185

Atorvastatin Epoxy Tetrahydrofuran Impurity	Drug Metabolite	Others
Atorvastatin Epoxy Tetrahydrofuran Impurity is an impurity isolated oxidative degradation products of Atorvastatin (HY-B0589). Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids.

HY-W014787S

Decanedioic acid-d4	Endogenous Metabolite	Metabolic Disease
Decanedioic acid-d₄ is the deuterium labeled Decanedioic acid[1]. Decanedioic acid, a normal urinary acid, is found to be associated with carnitine-acylcarnitine translocase deficiency and medium chain acyl-CoA dehydrogenase deficiency[2].

HY-W014787S1

Decanedioic acid-d16	Endogenous Metabolite	Metabolic Disease
Decanedioic acid-d₁₆ is the deuterium labeled Decanedioic acid[1]. Decanedioic acid, a normal urinary acid, is found to be associated with carnitine-acylcarnitine translocase deficiency and medium chain acyl-CoA dehydrogenase deficiency[2].

HY-135375

O-Methyl Atorvastatin hemicalcium	Drug Metabolite	Metabolic Disease Inflammation/Immunology
O-Methyl Atorvastatin (hemicalcium) is an impurity of Atorvastatin. Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids.

HY-13077

MK-8245 Trifluoroacetate 3 Publications Verification	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
MK-8245 trifluoroacetate is a liver-targeting inhibitor of stearoyl-CoA desaturase (SCD) with IC50 of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with anti-diabetic and anti-dyslipidemic efficacy.

HY-16901

Firsocostat 5+ Cited Publications ND-630; GS-0976; NDI-010976	Acetyl-CoA Carboxylase	Metabolic Disease
Firsocostat (ND-630; GS-0976; NDI-010976) is an acetyl-CoA carboxylase (ACC) inhibitor; inhibits human ACC1 and ACC2 with IC₅₀ values of 2.1 and 6.1 nM, respectively.

HY-147004

A-908292	Acetyl-CoA Carboxylase	Metabolic Disease
A-908292 is a potent and selective *acetyl-CoA* carboxylase 2 (ACC2) inhibitor, with an IC₅₀** of 23 nM for human ACC2. A-908292 can be used for the research of fatty acid metabolism.

HY-135373

Desfluoro-atorvastatin	Drug Metabolite	Metabolic Disease Inflammation/Immunology
Desfluoro-atorvastatin is an impurity of Atorvastatin. Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids.

HY-15197

ABT-046	Acyltransferase	Metabolic Disease
ABT-046 is a potent, selective, and orally active acyl CoA:diacylglycerol acyltransferase 1 (DGAT-1) inhibitor with IC₅₀s of both 8 nM against human and mouse DGAT-1.

HY-B0430

D-Pantothenic acid 2 Publications Verification Pantothenate; Vitamin B5	Endogenous Metabolite	Others
D-Pantothenic acid (Pantothenate) is an essential trace nutrient that functions as the obligate precursor of coenzyme A (CoA). D-Pantothenic acid plays key roles in myriad biological processes, including many that regulate carbohydrate, lipid, protein, and nucleic acid metabolism.

HY-B0430A

D-Pantothenic acid sodium 2 Publications Verification Sodium pantothenate; Vitamin B5 sodium	Apoptosis Endogenous Metabolite	Metabolic Disease
D-Pantothenic acid sodium (Sodium pantothenate) is an essential trace nutrient that functions as the obligate precursor of coenzyme A (CoA). D-Pantothenic acid sodium plays key roles in myriad biological processes, including many that regulate carbohydrate, lipid, protein, and nucleic acid metabolism.

HY-139577A

Ninerafaxstat trihydrochloride MB-1018972 trihydrochloride; IMB-101 trihydrochloride	Mitochondrial Metabolism	Cancer Metabolic Disease
Ninerafaxstat (IMB-1018972) trihydrochloride is a cardiac mitotrope agent. Ninerafaxstat trihydrochloride increases myocardial metabolic efficiency by shifting substrate utilization towards glucose through reducing fatty acid oxidation (inhibiting 3-ketoacyl CoA thiolase).

HY-136615

5-Hydroxydecanoate sodium	Potassium Channel	Neurological Disease
5-Hydroxydecanoate sodium is a selective ATP-sensitive K⁺ (K_ATP) channel blocker (IC₅₀ of ~30 μM). 5-Hydroxydecanoate sodium is a substrate for mitochondrial outer membrane acyl-CoA synthetase and has antioxidant activity.

HY-139577

Ninerafaxstat IMB-1018972; IMB-101	Mitochondrial Metabolism	Cancer Metabolic Disease
Ninerafaxstat (IMB-1018972) is a cardiac mitotrope agent. Ninerafaxstat increases myocardial metabolic efficiency by shifting substrate utilization towards glucose through reducing fatty acid oxidation (inhibiting 3-ketoacyl CoA thiolase).

HY-125130

Hesperetin 7-O-glucoside	HMG-CoA Reductase (HMGCR) Bacterial	Infection Metabolic Disease
Hesperetin 7-O-glucoside is produced by the enzymatic conversion of Hesperidin. Hesperetin 7-O-glucoside is a potent *human HMG-CoA* reductase inhibitor and also effectively inhibits the growth of Helicobacter pylori**. Antihypertensive effect.

HY-W020033

Lanosterol 1 Publications Verification	Endogenous Metabolite	Neurological Disease
Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol suppresses the aggregation and cytotoxicity of misfolded proteins linked with neurodegenerative diseases.

HY-127143

Sterculic acid	Stearoyl-CoA Desaturase (SCD)	Inflammation/Immunology
Sterculic acid is a stearoyl-CoA desaturase-1 (SCD1) inhibitor. Sterculic acid specifically inhibits the delta-9 desaturase (Δ9D) activity with an IC₅₀ value of 0.9 μM.

HY-125139

omega-3 Arachidonic acid ethyl ester ω-3 Arachidonic acid ethyl ester; (all-Z)-8,11,14,17-Eicosatetraenoic acid ethyl ester	Biochemical Assay Reagents	Others
omega-3 Arachidonic Acid ethyl ester is a rare polyunsaturated fatty acid found in very small amounts in dietary sources. Omega-3 fatty acids are known to be essential for the growth and development of infants, and they protect against heart disease, blood clots, high blood pressure, and inflammatory and autoimmune diseases. In human platelet membranes, omega-3 arachidonic acid inhibits arachidonyl-CoA synthetase with a Ki of 14 μM. It also inhibits arachidonoyl-CoA synthetase in calf brain extract with an IC50 of approximately 5 μM. Omega-3 ethyl arachidonate is the more lipophilic form of the free acid.

HY-147376

hACC2-IN-1	Acetyl-CoA Carboxylase	Metabolic Disease
hACC2-IN-1 is a potent *acetyl-CoA* carboxylase 2 (ACC2) inhibitor, with an IC₅₀ value of 2.5 μM (hACC2**). hACC2-IN-1 could be used for obesity research.

HY-134423S

Stearoyl coenzyme A-13C18 lithium	Isotope-Labeled Compounds	Others
Stearoyl coenzyme A-¹³C₁₈ (lithium) is the ¹³C labeled Stearoyl coenzyme A lithium[1]. Stearoyl coenzyme A (Stearoyl-CoA) lithium is an active compound that can be used as a substrate for the determination of stearoyl-Coenzyme desaturase in microsomes[2].

HY-13070

MK-8245 3 Publications Verification	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
MK-8245 is a potent, liver-targeted *stearoyl-CoA* desaturase (SCD) inhibitor, with IC₅₀**s of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with antidiabetic and antidyslipidemic efficacy.

HY-113679

Ceramides Mixture 1 Publications Verification	Telomerase	Endocrinology Metabolic Disease
Ceramides Mixture is an endogenous ceramide and consists of hydroxy and non-hydroxy fatty acid-containing ceramides. Ceramides Mixture is a main lipid component of the permeability barrier in epidermis. Ceramides Mixture is involved in the regulation of growth inhibition, cell cycle arrest, and modulation of telomerase activity.

HY-107396

YM-750	Acyltransferase	Cardiovascular Disease
YM-750 is a potent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor (IC₅₀=0.18 μM). ACAT catalyzes the formation of cholesteryl esters from cholesterol and long-chain fatty-acyl-coenzyme A.

HY-B1189S

Meglutol-d3 Dicrotalic acid-d₃; 3-Hydroxy-3-methylglutaric acid-d₃	Autophagy HMG-CoA Reductase (HMGCR) Endogenous Metabolite	Cardiovascular Disease
Meglutol-d₃ is the deuterium labeled Meglutol[1]. Meglutol is an antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids, and inhibits the activity of hydroxymethylglutarryl CoA reductases, which is the rate limiting enzyme in the biosynthesis of cholesterol.

HY-N6706

Enniatin complex	Bacterial Acyltransferase Apoptosis	Cancer Infection
Enniatin complex is a mixture of cyclohexadepsipeptides isolated largely from Fusarium species of fungi, and has ionophoric, antibiotic, and in vitro hypolipidaemic properties. Enniatin complex inhibits enzymes like acyl-CoA: cholesterol acyl transferase and induces apoptosis in several cancer lines .

HY-101873S

Atorvastatin lactone-d5	Isotope-Labeled Compounds HMG-CoA Reductase (HMGCR)	Metabolic Disease Inflammation/Immunology
Atorvastatin lactone-d₅ is a deuterated form of Atorvastatin lactone (HY-101873). Atorvastatin lactone is a proagent form of atorvastatin. Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor[1].

HY-139180

PRGL493 1 Publications Verification	Others	Cancer
PRGL493 is a potent and selective *long-chain acyl-CoA* synthetase 4 (ACSL4)** inhibitor. PRGL493 blocks cell proliferation and tumor growth in both breast and prostate cellular and animal models. PRGL493 is used for cancer research.

HY-B0589

Atorvastatin 20+ Cited Publications	HMG-CoA Reductase (HMGCR) Autophagy	Metabolic Disease Inflammation/Immunology
Atorvastatin is an orally active *HMG-CoA* reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC₅₀s of 0.39 μM and 2.39 μM, respectively.

HY-14664A

Fluvastatin sodium 10+ Cited Publications XU 62-320	HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis	Cardiovascular Disease Cancer
Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive *HMG-CoA* reductase** inhibitor with an IC₅₀ of 8 nM. Fluvastatin sodium protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.

HY-109591S

Oleoyl coenzyme A-13C18 lithium	Isotope-Labeled Compounds	Others
Oleoyl coenzyme A-¹³C₁₈ (lithium) is the ¹³C labeled Oleoyl Coenzyme A lithium[1]. Oleoyl coenzyme A (Oleoyl-CoA) is a thioester of oleic acid and coenzyme A. Oleoyl coenzyme A has a role as an Escherichia coli metabolite and a mouse metabolite[2][3].

HY-135377

Atorvastatin 3-Deoxyhept-2E-Enoic Acid (2E)-2,3-Dehydroxy Atorvastatin	Drug Metabolite	Metabolic Disease Inflammation/Immunology
Atorvastatin 3-Deoxyhept-2E-Enoic Acid ((2E)-2,3-Dehydroxy Atorvastatin) is an impurity of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids.

HY-12942

PF-05175157 1 Publications Verification	Acetyl-CoA Carboxylase	Metabolic Disease
PF-05175157 is broad spectrum *acetyl-CoA* carboxylase (ACC) inhibitor with IC₅₀**s of 27.0, 33.0, 23.5 and 50.4 nM for ACC1 (human), ACC2 (human), ACC1 (rat), ACC2 (rat), respectively.

HY-113342

7-Ketocholesterol	Endogenous Metabolite	Metabolic Disease
7-Ketocholesterol, toxic oxysterol, inhibits the rate-limiting step in bile acid biosynthesis cholesterol 7 alpha-hydroxylase, as well as strongly inhibiting *HMG-CoA* reductase** (the rate-limiting enzyme in cholesterol biosynthesis). 7-Ketocholesterol induces cell apoptosis.

HY-N6807

Elemicin	Stearoyl-CoA Desaturase (SCD) Influenza Virus	Cancer Infection
Elemicin is a alkenylbenzene widely distributed in many herbs and spices. Elemicin inhibits *Stearoyl-CoA* Desaturase 1 (SCD1)** by metabolic activation. Elemicin is one of the main components in aromatic food and has antimicrobial, antioxidant, and antiviral activities. Elemicin possesses genotoxicity and carcinogenicity.

HY-121407

Lateritin	Acyltransferase	Infection Cancer
Lateritin is a potent inhibitor of *acyl-CoA:cholesterol acyltransferase* (ACAT), isolated from the mycelial cake of Gibberella lateritium IFO 7188. Lateritin also inhibits the growth of a mini-panel of human cancer cell lines, gram-positive bacteria, and Candida albicans.

HY-14664

Fluvastatin 10+ Cited Publications XU 62-320 free acid	HMG-CoA Reductase (HMGCR) Autophagy	Cancer Cardiovascular Disease
Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive *HMG-CoA* reductase** inhibitor with an IC₅₀ of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.

HY-108257

Atorvastatin sodium	HMG-CoA Reductase (HMGCR) Autophagy	Metabolic Disease Inflammation/Immunology
Atorvastatin sodium is an orally active *HMG-CoA* reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin sodium inhibits human SV-SMC proliferation and invasion with IC₅₀s of 0.39 μM and 2.39 μM, respectively.

HY-16946

CP-610431	Acetyl-CoA Carboxylase	Metabolic Disease
CP-610431 is a reversible, ATP-uncompetitive, isozyme-nonselective acetyl-CoA carboxylase (ACC) inhibitor. CP-610431 inhibits ACC1 and ACC2 with IC₅₀s of ~50 nM. CP-610431 can be used for the research of metabolic syndrome.

HY-W050031

(S)-3-Hydroxybutanoic acid 1 Publications Verification (S)-β-Hydroxybutanoic acid; L-(+)-3-Hydroxybutyric acid; L-β-Hydroxybutyric acid	Endogenous Metabolite	Others
(S)-3-Hydroxybutanoic acid is a normal human metabolite, that has been found elevated in geriatric patients remitting from depression. In humans, 3-Hydroxybutyric acid is synthesized in the liver from acetyl-CoA, and can be used as an energy source by the brain when blood glucose is low.

HY-136346S

Ortho-hydroxy atorvastatin lactone-d5	Drug Metabolite	Cardiovascular Disease
Ortho-hydroxy atorvastatin lactone-d₅ is deuterium labeled 2-Hydroxy atorvastatin lactone. 2-Hydroxy atorvastatin lactone is a metabolite of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids[1][2].

HY-117651

2-Fluoropalmitic acid	Acyltransferase	Cancer
2-Fluoropalmitic acid, an acyl-CoA synthetase inhibitor, acts as a candidate anti-glioma agent. 2-Fluoropalmitic acid suppresses the viability and stem-like phenotype of glioma stem cells (GSCs). 2-Fluoropalmitic acid also inhibits proliferation and invasion of glioma cell lines.

HY-B0589E

Atorvastatin hemicalcium trihydrate	HMG-CoA Reductase (HMGCR) Autophagy	Metabolic Disease Inflammation/Immunology
Atorvastatin hemicalcium trihydrate is an orally active *HMG-CoA* reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium trihydrate inhibits human SV-SMC proliferation and invasion with IC₅₀s of 0.39 μM and 2.39 μM, respectively.

HY-N3806

Enniatin B	Acyltransferase ERK	Cancer Infection Cardiovascular Disease
Enniatin B is a Fusarium mycotoxin. Enniatin B inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC₅₀ of 113 μM in an enzyme assay using rat liver microsomes. Enniatins B decreases the activation of ERK (p44/p42).

HY-135151

Difluoro atorvastatin Fluoroatorvastatin	Drug Metabolite	Cardiovascular Disease
Difluoro atorvastatin (Fluoroatorvastatin) is an impurity of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC₅₀s of 0.39 μM and 2.39 μM, respectively.

HY-B0589A

(rel)-Atorvastatin	HMG-CoA Reductase (HMGCR) Autophagy	Metabolic Disease Inflammation/Immunology
(rel)-Atorvastatin, a relative configuration of Atorvastatin. Atorvastatin is an orally active *HMG-CoA* reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC₅₀s of 0.39 μM and 2.39 μM, respectively.

HY-108341

PF-06424439	Acyltransferase	Metabolic Disease
PF-06424439 is an oral, potent and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC₅₀ of 14 nM. PF-06424439 is slowly reversible, time-dependent inhibitor, which inhibits DGAT2 in a noncompetitive mode with respect to the acyl-CoA substrate.

HY-113067S

Phytanic acid-d3	Endogenous Metabolite	Metabolic Disease
Phytanic acid-d₃ is the deuterium labeled Phytanic acid[1]. Phytanic acid is an endogenous metabolite present in Blood that can be used for the research of Zellweger Syndrome, Alpha Methylacyl CoA Racemase Deficiency, Rhizomelic Chondrodysplasia Punctata and Infantile Refsum Disease[2][3][4][5][6].

HY-135425

10,12-Tricosadiynoic acid 2 Publications Verification	Acyltransferase	Metabolic Disease
10,12-Tricosadiynoic acid is a highly specific, selective, high affinity and orally active *acyl-CoA* oxidase-1 (ACOX1)** inhibitor. 10,12-Tricosadiynoic acid can treat high fat diet- or obesity-induced metabolic diseases by improving mitochondrial lipid and ROS metabolism.

HY-N6707

Triacsin C 1 Publications Verification WS 1228A; FR 900190	Parasite	Infection
Triacsin C (WS 1228A), a natural intracellular long-chain acyl-CoA synthetases (ACSL) inhibitor, is from Streptomyces aureofaciens. Triacsin C inhibits TAG accumulation into lipid droplets (LD) by suppressing ACSL activity. Triacsin C is found to be highly effective against rotavirus replication.

HY-115734

Phenylpyropene C S14-95	Acyltransferase	Inflammation/Immunology
Phenylpyropene C (S14-95), a JAK/STAT pathway inhibitor, can inhibit IFN-γ mediated expression of the reporter gene (IC₅₀=5.4~10.8 μM). Phenylpyropene C also is an inhibitor of *acyl-CoA, with an IC₅₀* of 16.0 μM.

HY-B0589C

(3S,5S)-Atorvastatin	Cytochrome P450	Metabolic Disease
(3S,5S)-Atorvastatin is a inactive enantiomer of Atorvastatin. (3S,5S)-Atorvastatin can activate pregnane X receptor (PXR). Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids.

HY-134421

2-Butenoyl coenzyme A lithium	Biochemical Assay Reagents	Others
2-Butenoyl coenzyme A (lithium), an active compound, can be used as a substrate for plasmodium falciparum enyl-ACP reductases and other enyl-CoA reductases. 2-Butenoyl coenzyme A lithium can be used as a substrate analogue to study the kinetics of β-hydroxyacyl-acyl-carrier protein (ACP) dehydratase (FabZ).

HY-B0589S1

Atorvastatin-d5 sodium	HMG-CoA Reductase (HMGCR) Autophagy	Metabolic Disease Inflammation/Immunology
Atorvastatin-d₅ (sodium) is the deuterium labeled Atorvastatin sodium. Atorvastatin sodium is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin sodium inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3][4].

HY-141699

FATP1-IN-1	Others	Metabolic Disease
FATP1-IN-1 (compound 5k) is a fatty acid transport protein 1 (FATP1) inhibitor. FATP1-IN-1 is an inhibition of recombinant human or mouse acyl-CoA synthetase activity of FATP1, with the IC₅₀ values of 0.046 μM or 0.60 μM, respectively.

HY-108341A

PF-06424439 methanesulfonate 4 Publications Verification	Acyltransferase	Metabolic Disease
PF-06424439 methanesulfonate is an oral, potent and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC₅₀ of 14 nM. PF-06424439 methanesulfonate is slowly reversible, time-dependent inhibitor, which inhibits DGAT2 in a noncompetitive mode with respect to the acyl-CoA substrate.

HY-119695B

Simvastatin acid calcium hydrate Tenivastatin calcium hydrate	HMG-CoA Reductase (HMGCR) Reactive Oxygen Species	Inflammation/Immunology Cardiovascular Disease
Simvastatin acid (Tenivastatin) calcium hydrate is a potent *HMG-CoA* reductase (HMGCR) inhibitor. Simvastatin acid calcium hydrate reduces Indoxyl sulfate-mediated reactive oxygen species** (ROS) production in human cardiomyocytes. Simvastatin acid calcium hydrate can also modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene.

HY-124751

YTX-465	Stearoyl-CoA Desaturase (SCD)	Neurological Disease
YTX-465 is a *stearoyl-CoA* desaturase (Ole1/SCD) inhibitor. YTX-465 inhibits Ole1 and SCD1 with IC₅₀**s of 0.039 μM and 30.4 μM, respectively. YTX-465 can be used in the research of Parkinson’s disease and other synucleinopathies.

HY-119695A

Simvastatin acid ammonium Tenivastatin ammonium	HMG-CoA Reductase (HMGCR) Reactive Oxygen Species	Inflammation/Immunology Cardiovascular Disease
Simvastatin acid (Tenivastatin) ammonium is a potent *HMG-CoA* reductase (HMGCR) inhibitor. Simvastatin acid ammonium reduces Indoxyl sulfate-mediated reactive oxygen species** (ROS) production in human cardiomyocytes. Simvastatin acid ammonium can also modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene.

HY-B0589S

Atorvastatin-d5 hemicalcium	HMG-CoA Reductase (HMGCR) Autophagy	Metabolic Disease Inflammation/Immunology
Atorvastatin-d₅ (hemicalcium) is the deuterium labeled Atorvastatin. Atorvastatin hemicalcium is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3].

HY-12325

GSK2194069 2 Publications Verification	Fatty Acid Synthase (FASN)	Cancer
GSK2194069 is a potent inhibitor of β-ketoyl reductase (KR) of fatty acid synthase (FASN), with an IC₅₀ value of 7.7 nM. GSK2194069 shows specifically inhibitory effect on FAS expressing cancer cells, by acting potent efficacy on acetoacetyl-CoA, NADPH with IC₅₀ or K_i values of 4.8 nM and 5.6 nM, respectively.

HY-119695

Simvastatin acid Tenivastatin	HMG-CoA Reductase (HMGCR) Reactive Oxygen Species	Cancer Cardiovascular Disease
Simvastatin acid (Tenivastatin), a hydrolysate of Simvastatin (HY-17502), is a *HMG-CoA* reductase (HMGCR) inhibitor. Simvastatin acid reduces Indoxyl sulfate-mediated reactive oxygen species** (ROS) production in human cardiomyocytes. Simvastatin acid can also modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene.

HY-135374

(3R,5S)-Atorvastatin sodium	Drug Metabolite	Metabolic Disease Inflammation/Immunology
(3R,5S)-Atorvastatin sodium is an impurity of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC₅₀s of 0.39 μM and 2.39 μM, respectively.

HY-115292

Simvastatin hydroxy acid sodium Tenivastatin sodium; Simvastatin Impurity A sodium	HMG-CoA Reductase (HMGCR) Reactive Oxygen Species	Inflammation/Immunology Cardiovascular Disease
Simvastatin hydroxy acid (Tenivastatin) sodium is a potent *HMG-CoA* reductase (HMGCR) inhibitor. Simvastatin hydroxy acid sodium reduces Indoxyl sulfate-mediated reactive oxygen species** (ROS) production in human cardiomyocytes. Simvastatin hydroxy acid sodium can also modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene.

HY-135981

CMS-121 1 Publications Verification	Acetyl-CoA Carboxylase	Inflammation/Immunology Neurological Disease
CMS-121 is a quinolone derivative and an orally active *acetyl-CoA* carboxylase 1 (ACC1) inhibitor. CMS-121 protects HT22 cells against ischemia and oxidative damage with EC₅₀** values of 7 nM and 200 nM, respectively. CMS-121 has strong neuroprotective, anti-inflammatory, antioxidative and renoprotective activities.

HY-109523

Cerivastatin sodium	HMG-CoA Reductase (HMGCR) Ferroptosis	Cancer Cardiovascular Disease
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active *HMG-CoA* reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA** inhibition, and has anti-cancer effect.

HY-B0430S

Pantothenic acid-13C3,15N hemicalcium	Endogenous Metabolite	Others
Pantothenic acid-¹³C₃,¹⁵N (hemicalcium) is the ¹³C-labeled and ¹⁵N-labeled D-Pantothenic acid. D-Pantothenic acid is an essential trace nutrient that functions as the obligate precursor of coenzyme A (CoA). D-Pantothenic acid plays key roles in myriad biological processes, including many that regulate carbohydrate, lipid, protein, and nucleic acid metabolism[1].

HY-129458

Cerivastatin	HMG-CoA Reductase (HMGCR) Ferroptosis	Cancer Cardiovascular Disease
Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active *HMG-CoA* reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA** inhibition, and has anti-cancer effect.

HY-100793

SR12813 2 Publications Verification GW 485801	HMG-CoA Reductase (HMGCR) Autophagy	Metabolic Disease
SR12813 (GW 485801) is an inhibitor of *3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, with an IC₅₀ value of 0.85 μM. SR12813 is also an efficient agonist of human pregnane X receptor (hPXR*). SR12813 can strongly bind to hPXR but not to mouse PXR (mPXR).

HY-B0399

L-Carnitine 5+ Cited Publications (R)-Carnitine; Levocarnitine	Endogenous Metabolite	Neurological Disease Cancer
L-Carnitine ((R)-Carnitine), a highly polar, small zwitterion, is an essential co-factor for the mitochondrial β-oxidation pathway. L-Carnitine functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by β-oxidation. L-Carnitine is an antioxidant. L-Carnitine can ameliorate metabolic imbalances in many inborn errors of metabolism.

HY-B2246

L-Carnitine hydrochloride 5+ Cited Publications (R)-Carnitine hydrochloride; Levocarnitine hydrochloride	Endogenous Metabolite	Metabolic Disease Cancer
L-Carnitine hydrochloride ((R)-Carnitine hydrochloride), a highly polar, small zwitterion, is an essential co-factor for the mitochondrial β-oxidation pathway. L-Carnitine hydrochloride functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by β-oxidation. L-Carnitine hydrochloride is an antioxidant. L-Carnitine hydrochloride can ameliorate metabolic imbalances in many inborn errors of metabolism.

HY-15142

Doxorubicin hydrochloride Maximum Cited Publications 318 Publications Verification Hydroxydaunorubicin hydrochloride	Topoisomerase ADC Cytotoxin AMPK Autophagy Apoptosis HIV HBV Mitophagy Antibiotic Bacterial	Cancer Infection
Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC₅₀s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy.

HY-117769

GSK837149A	Fatty Acid Synthase (FASN)	Metabolic Disease
GSK837149A is a selective inhibitor of human Fatty Acid Synthase (FASN) targeting the KR domain. GSK837149A has reversible inhibition effect on FASN and selectivity for type I FASN (K_i=30 nM). GSK837149A is also a competitive inhibitor of NADPH and a non-competitive inhibitor of acetoacetyl-CoA. GSK837149A can be used for the research of obesity and breast cancer.

HY-107571

VULM 1457	Acyltransferase	Metabolic Disease Cardiovascular Disease
VULM 1457 is a potent inhibitor of cholesterol acyltransferase (acyl-CoA). VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM 1457 has the potential for the research of diabetes mellitus and hypercholesterolaemia.

HY-17379

Atorvastatin hemicalcium salt 20+ Cited Publications CI-981; Atorvastatin hemicalcium	HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis	Metabolic Disease Inflammation/Immunology
Atorvastatin hemicalcium salt (CI-981) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion with IC₅₀s of 0.39 μM and 2.39 μM, respectively.

HY-17504AS

Rosuvastatin D3 ZD 4522 d₃	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel	Metabolic Disease Cardiovascular Disease
Rosuvastatin-d₃ is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM[1]. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals[2].

HY-17504B

Rosuvastatin Sodium 5+ Cited Publications ZD 4522 Sodium; X-Plended Sodium; Crestor Sodium	HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Bacterial	Metabolic Disease Cardiovascular Disease
Rosuvastatin Sodium is a competitive *HMG-CoA* reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀** of 195 nM. Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.

HY-17408

Mevastatin 5+ Cited Publications Compactin; ML236B	HMG-CoA Reductase (HMGCR) Bacterial Autophagy Apoptosis Antibiotic	Cancer Infection Metabolic Disease Neurological Disease Cardiovascular Disease
Mevastatin (Compactin) is a first *HMG-CoA* reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis**, arrests cancer cells in G₀/G₁ phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment.

HY-15142A

Doxorubicin Hydroxydaunorubicin	ADC Cytotoxin Antibiotic Bacterial Topoisomerase AMPK HIV Autophagy Mitophagy Apoptosis HBV	Cancer Infection
Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin inhibits topoisomerase II with an IC₅₀ of 2.67 μM, thus stopping DNA replication. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy. Doxorubicin inhibits human DNA topoisomerase I with an IC₅₀ of 0.8 μM.

HY-134901

WM-3835 1 Publications Verification	Histone Acetyltransferase Apoptosis	Cancer
WM-3835 is a potent and high-specific HBO1 (KAT7 or MYST2) inhibitor and binds directly to the acetyl-CoA binding site of HBO1 33. WM-3835 activates apoptosis while inhibits osteosarcoma (OS) cell proliferation, migration and invasion. WM-3835 has antitumor activity and potently inhibits pOS-1 xenograft growth in mice.

HY-148104

ACSS2-IN-2	Others	Cancer Infection Metabolic Disease Inflammation/Immunology Neurological Disease
ACSS2-IN-2 is an *acyl-CoA* synthetase short-chain family member 2 (ACSS2) inhibitor. ACSS2-IN-2 can inhibit ACSS2 activity with an IC₅₀** value of 3.8 nM. ACSS2-IN-2 can be used for the research of several diseases, such as viral infection, metabolic disorders, neuropsychiatric diseases, inflammatory/autoimmune conditions and cancer.

HY-B0968A

Trimetazidine 4 Publications Verification	Autophagy	Cardiovascular Disease
Trimetazidine is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC₅₀ of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine triggers autophagy. Trimetazidine is also a *3-hydroxyacyl-CoA* dehydrogenase (HADHA)** inhibitor.

HY-17504

Rosuvastatin Calcium 5+ Cited Publications Rosuvastatin hemicalcium; ZD 4522 Calcium	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Metabolic Disease Cardiovascular Disease Cancer
Rosuvastatin Calcium is a competitive *HMG-CoA* reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC₅₀** of 195 nM. Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.

HY-14664DS

(3S,5R)-Fluvastatin-d6 (3S,5R)-XU 62-320-d₆ free acid	Autophagy	Cancer Cardiovascular Disease
(3S,5R)-Fluvastatin-d₆ is the deuterium labeled (3S,5R)-Fluvastatin sodium. Fluvastatin is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway[1].

HY-14664B

(3R,5S)-Fluvastatin (3R,5S)-XU 62-320 free acid	HMG-CoA Reductase (HMGCR) Autophagy	Cancer Cardiovascular Disease
(3R,5S)-Fluvastatin is the 3R,5S-isomer Fluvastatin. Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive *HMG-CoA* reductase** inhibitor with an IC₅₀ of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.

HY-B0968

Trimetazidine dihydrochloride 4 Publications Verification	Autophagy	Cardiovascular Disease
Trimetazidine dihydrochloride is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC₅₀ of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine dihydrochloride is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine dihydrochloride triggers autophagy. Trimetazidine dihydrochloride is also a *3-hydroxyacyl-CoA* dehydrogenase (HADHA)** inhibitor.

HY-112083

BAY-3827 2 Publications Verification	AMPK	Cancer
BAY-3827 is a potent and selective AMPK inhibitor with IC₅₀ values of 1.4 nM at low (10 µM ATP concentration) and 15 nM at high (2 mM ATP concentration). BAY-3827 shows over 500-fold selectivity for most of the 331 kinases. BAY-3827 prevents phosphorylation of acetyl-CoA carboxylase 1 and shows strongest anti-proliferative activity in androgen-dependent prostate cancer cell lines.

HY-14664CS

(3S,5R)-Fluvastatin-d6 sodium (3S,5R)-XU 62-320-d₆	HMG-CoA Reductase (HMGCR)	Cancer Cardiovascular Disease
(3S,5R)-Fluvastatin-d₆ (sodium) is the deuterium labeled (3S,5R)-Fluvastatin sodium. Fluvastatin is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway[1].

HY-B2246S

L-Carnitine-d9 chloride (R)-Carnitine-d₉ (chloride); Levocarnitine-d₉ (chloride)	Endogenous Metabolite	Metabolic Disease
L-Carnitine-d₉ (chloride)e is the deuterium labeled L-Carnitine chloride. L-Carnitine chloride, a highly polar, small zwitterion, is an essential co-factor for the mitochondrial β-oxidation pathway. L-Carnitine chloride functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by β-oxidation. L-Carnitine chloride is an antioxidant. L-Carnitine chloride can ameliorate metabolic imbalances in many inborn errors of metabolism[1][2][3].

HY-100671

L002	Histone Acetyltransferase STAT	Cancer Inflammation/Immunology
L002 is a potent, cell permeable, reversible and specific acetyltransferase p300 (KAT3B) inhibitor with an IC₅₀ of 1.98 μM. L002 binds the acetyl-CoA pocket and competitively inhibits the FATp300 catalytic domain, blocks histone acetylation and p53 acetylation, and inhibits STAT3 activation. L002 has the potential for hypertension‐induced cardiac hypertrophy and fibrogenesis treatment.

HY-B0968S

Trimetazidine-d8 dihydrochloride	Autophagy	Cardiovascular Disease
Trimetazidine-d₈ (dihydrochloride) is the deuterium labeled Trimetazidine dihydrochloride. Trimetazidine dihydrochloride is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine dihydrochloride is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine dihydrochloride triggers autophagy. Trimetazidine dihydrochloride is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor[1][2][3][4].

HY-14664C

(3S,5R)-Fluvastatin sodium (3S,5R)-XU 62-320	HMG-CoA Reductase (HMGCR)	Cancer Cardiovascular Disease
(3S,5R)-Fluvastatin sodium ((3S,5R)-XU 62-320) is the (3S,5R)-enantiomer of Fluvastatin. Fluvastatin is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC₅₀ of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.

HY-B0399S

L-Carnitine-d9 (R)-Carnitine-d₉; Levocarnitine-d₉	Endogenous Metabolite	Metabolic Disease Neurological Disease
L-Carnitine-d₉ is the deuterium labeled L-Carnitine. L-Carnitine (Levocarnitine) is an endogenous molecule involved in fatty acid metabolism, biosynthesized within the human body using amino acids: L-lysine and L-methionine, as substrates. L-Carnitine functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by β-oxidation. L-carnitine can ameliorate metabolic imbalances in many inborn errors of metabolism[1][2].

HY-N3807

Enniatin B1	Acyltransferase ERK NF-κB	Cancer Infection Cardiovascular Disease
Enniatin B1 is a Fusarium mycotoxin. Enniatin B1 inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC₅₀ of 73 μM in an enzyme assay using rat liver microsomes. Enniatin B1 crosss the blood-brain barrier. Enniatin B1 decreases the activation of ERK (p44/p42). Enniatin B1 inhibits moderately TNF-α-induced NF-κB activation.

HY-17504A

Rosuvastatin ZD 4522	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Metabolic Disease Cardiovascular Disease Cancer
Rosuvastatin (ZD 4522) is a competitive *HMG-CoA* reductase inhibitor with an IC₅₀ of 11 nM. Rosuvastatin potently blocks hERG current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.

HY-14664F

(3R,5S)-Fluvastatin sodium (3R,5S)-XU 62-320	Autophagy HMG-CoA Reductase (HMGCR)	Cancer
(3R,5S)-Fluvastatin ((3R,5S)-XU 62-320) sodium is the 3R,5S-isomer Fluvastatin. Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.

HY-17504R

Rosuvastatin Calcium (Standard) Rosuvastatin hemicalcium (Standard); ZD 4522 Calcium (Standard)	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Metabolic Disease Cardiovascular Disease Cancer
Rosuvastatin (Calcium) (Standard) is the analytical standard of Rosuvastatin (Calcium). This product is intended for research and analytical applications. Rosuvastatin Calcium is a competitive *HMG-CoA* reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC₅₀** of 195 nM. Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.

HY-17504C

(3R,5R)-Rosuvastatin	HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy	Metabolic Disease Cardiovascular Disease
(3R,5R)-Rosuvastatin is the (3R,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive *HMG-CoA* reductase inhibitor with an IC₅₀ of 11 nM. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC₅₀ of 195 nM. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.

HY-17504D

(3S,5R)-Rosuvastatin	HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy	Metabolic Disease Cardiovascular Disease
(3S,5R)-Rosuvastatin is the (3S,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive *HMG-CoA* reductase inhibitor with an IC₅₀ of 11 nM. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC₅₀ of 195 nM. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.

HY-106281

Bemfivastatin PPD 10558	HMG-CoA Reductase (HMGCR)	Metabolic Disease Cardiovascular Disease
Bemfivastatin (PPD 10558) is an orally active, HMG-CoA Reductase (HMGCR) inhibitor, also known as Statin. Bemfivastatin enhances the activity of liver extraction. Bemfivastatin exhibits little developmental toxicity effects in pregnant rats and rabbits via daily oral doses during organogenesis period. The no observed adverse effect level (NOAEL) are ≥320 mg/kg/day for rats developmental toxicity, 12.5 mg/kg/day for rabbits maternal toxicity, and 25 mg/kg/day for rabbits developmental toxicity, respectively. Bemfivastatin can be used for research on Statin-related hypercholesterolemic myalgia with inability to tolerate statins.

HY-124346

T-3364366	Others	Metabolic Disease
T-3364366 is a reversible, slow-binding, thienopyrimidinone delta-5 desaturase (D5D) inhibitor with IC₅₀s of 1.9 nM and 2.1 nM in HepG2 and RLN-10 cells, respectively. T-3364366 exhibits potent D5D (IC₅₀0=19 nM) inhibitory activity and excellent selectivity away from delta-6 desaturase (D6D, IC₅₀=6200 nM) and delta-9 desaturase (stearoyl-CoA desaturase, SCD,₅₀ >10000 nM) in the enzymatic activity assay.

HY-100401A

Pactimibe sulfate CS-505	Acyltransferase	Cardiovascular Disease
Pactimibe sulfate (CS-505) is a dual ACAT1/2 inhibitor with IC₅₀s of 4.9 μM and 3.0 μM, respectively. Pactimibe sulfate (CS-505) inhibits ACAT with IC₅₀s of 2.0 μM, 2.7 μM, 4.7 μM in the liver, macrophages and THP-1 cells, respectively. Pactimibe sulfate (CS-505) noncompetitively inhibits *oleoyl-CoA* with a K_i value of 5.6 μM. Moreover, Pactimibe sulfate (CS-505) obviously inhibits cholesteryl ester formation with an IC₅₀ of 6.7 μM. Pactimibe sulfate (CS-505) possesses anti-atherosclerotic potential with lowering plasma cholesterol activity.

HY-100401

Pactimibe CS-505 free base	Acyltransferase	Cardiovascular Disease
Pactimibe (CS-505 free base) is a dual ACAT1/2 inhibitor with IC₅₀s of 4.9 μM and 3.0 μM, respectively. Pactimibe (CS-505 free base) inhibits ACAT with IC₅₀s of 2.0 μM, 2.7 μM, 4.7 μM in the liver, macrophages and THP-1 cells, respectively. Pactimibe (CS-505 free base) noncompetitively inhibits *oleoyl-CoA* with a K_i value of 5.6 μM. Moreover, Pactimibe (CS-505 free base) obviously inhibits cholesteryl ester formation with an IC₅₀ of 6.7 μM. Pactimibe (CS-505 free base) possesses anti-atherosclerotic potential with lowering plasma cholesterol activity.

Cat. No.	Product Name

HY-L091

Lipid Metabolism Compound Library

580 compounds

Lipids are a fundamental class of organic molecules implicated in a wide range of biological processes, and based on this can be broadly classified into five categories: fatty acids, triacylglycerols (TAGs), phospholipids, sterol lipids and sphingolipids. Lipids play a crucial role in different metabolic pathways and cellular functions. Lipid metabolism is an important physiological process that is related to nutrient adjustment, hormone regulation, and homeostasis. Lipid metabolism dysregulation is associated with many diseases such as obesity, liver disease, aging and inflammation.

MCE offers a unique collection of 580 compounds related to lipid metabolism, which target relevant targets in the process of lipid metabolism, such as ATGL, MAGL, FAAH, acetyl-Coa Carboxylase, FASN, etc. MCE lipid metabolism compound library is a useful tool for research lipid metabolism and drug discovery of diseases related to lipid metabolism.

HY-L087

Anti-Obesity Compound Library

2103 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 2103 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

HY-L012

Metabolism/Protease Compound Library

3993 compounds

Metabolism is the set of life-sustaining chemical reactions in organisms. Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of natural product small molecules within a cell or tissue. Acting as catalysts, enzymes are crucial to metabolism - they allow a reaction to proceed more rapidly - and they also allow the regulation of the rate of a metabolic reaction. Proteases are used throughout an organism for various metabolic processes. Proteases control a great variety of physiological processes that are critical for life, including the immune response, cell cycle, cell death, wound healing, food digestion, and protein and organelle recycling. Imbalances in metabolic activities have been found to be critical in a number of pathologies, such as cardiovascular diseases, inflammation, cancer, and neurodegenerative diseases.

MCE designs a unique collection of 3993 Metabolism/Protease-related small molecules that act as a useful tool for drug discovery of metabolism-related diseases.

HY-L148

TCA Cycle Compound Library

47 compounds

The TCA cycle (tricarboxylic acid cycle)—is also known as the Krebs cycle or the citric acid cycle (CAC). The TCA cycle is a series of chemical reactions that release stored energy through the oxidation of acetyl-CoA in carbohydrates, fats, and proteins.

For decades, the TCA cycle has been considered as the central pathway for cell oxidative phosphorylation to produce energy and biosynthesis. Research shows that TCA cycle is associated with many diseases, especially cancer. In colon carcinoma, liver cancer and other cancers, there are mutations that lead to the imbalance of TCA cycle metabolites, indicating that TCA cycle may be related to the occurrence of cancer. Understanding the role and molecular mechanism of TCA cycle in inhibiting or promoting cancer progression will promote the development of new metabolite-based cancer treatment methods in the future.

MCE supplies a unique collection of 47 compounds related to the TCA cycle. MCE TCA Cycle Compound Library is a useful tool for the TCA cycle related research and anti-cancer drug development.

Cat. No.	Product Name	Type

HY-W004784

3-Butynoic acid

Biochemical Assay Reagents

3-Butynoic acid is an inhibitor of acyl CoA dehydrogenase.

HY-N7392

Acetoacetyl-CoA	Biochemical Assay Reagents
Acetoacetyl CoA is the precursor of HMG-CoA in the mevalonate pathway. Acetoacetyl-CoA thiolase catalyzes the reaction to form acetoacetyl-CoA from two acetyl-CoA molecules. Acetoacetyl CoA is essential for cholesterol biosynthesis. Acetoacetyl-CoA is also a intermediate in the biological breakdown and synthesis of fatty acids.

HY-P2943

Phosphate acetyltransferase	Enzyme
Phosphate acetyltransferase is a transferase enzyme, is often used in biochemical studies. Phosphate acetyltransferase catalyzes the reversible transfer of the acetyl group from acetyl-P to CoA forming acetyl-CoA and inorganic phosphate, participating to acetate assimilation/dissimilation reactions.

HY-131303

Heptadecanoyl Coenzyme A Heptadecanoyl-coa	Biochemical Assay Reagents
Heptadecanoyl Coenzyme A (Heptadecanoyl-CoA), long-chain acyl-coenzymes A (acyl-CoAs) (LCACoA), is an intermediate in lipid metabolism. Heptadecanoyl Coenzyme A can be used for the research of glucose metabolism.

HY-P2827

Acetyl-CoA synthetase

ACS
Enzyme

Acetyl-CoA synthetase (ACS) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-154922

Palmitoyl coenzyme A Palmitoyl coa	Biochemical Assay Reagents
Palmitoyl coenzyme A (Palmitoyl CoA) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-154923

Pentadecanoyl coenzyme A Pentadecanoyl-coa	Biochemical Assay Reagents
Pentadecanoyl coenzyme A (Pentadecanoyl-CoA) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-E70009

*Acyl-CoA* oxidase** ACO	Enzyme
Acyl-CoA oxidase (ACO) catalyses the first and rate-determining step of the peroxisomal beta-oxidation of fatty acids and a major producer of hydrogen peroxide (H₂O₂).

HY-134423

Stearoyl coenzyme A lithium Stearoyl-coa lithium	Biochemical Assay Reagents
Stearoyl coenzyme A (Stearoyl-CoA) lithium is an active compound that can be used as a substrate for the determination of stearoyl-Coenzyme desaturase in microsomes.

HY-109591A

Oleoyl coenzyme A lithium Oleoyl-coa lithium	Biochemical Assay Reagents
Oleoyl coenzyme A (Oleoyl-CoA) lithium is a thioester of oleic acid and coenzyme A. Oleoyl coenzyme A lithium has a role as an Escherichia coli metabolite and a mouse metabolite.

HY-134422

Isobutyryl coenzyme A lithium Isobutyryl coa lithium	Biochemical Assay Reagents
Isobutyryl coenzyme A (Isobutyryl CoA) lithium is A coenzyme A involved in the metabolic pathway of fatty acids. Isobutyryl coenzyme A lithium is made by combining isobutyric acid (short chain branched fatty acid) with coenzyme A.

HY-111487

*α-Methylacyl-CoA* racemase 1**	Enzyme
α-methylacyl-CoA racemase 1 is an enzyme that catalyzes a key chiral inversion step in the metabolism of branched-chain fatty acids, and used as a maker in prostate and other cancer.

HY-134427

Palmitoyl coenzyme A lithium Palmitoyl coa lithium	Biochemical Assay Reagents
Palmitoyl coenzyme A lithium is an acyl-CoA thioester that can be transported into the mitochondrial matrix via the carnitine shuttle system and is involved in β-oxidation. Palmitoyl coenzyme A lithium can also be used as a substrate for sphingosine biosynthesis.

HY-113596A

Acetyl coenzyme A lithium

Acetyl-coa lithium

Biochemical Assay Reagents

Acetyl-coenzyme A (Acetyl-CoA) lithium is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A lithium, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A lithium is also a key precursor of lipid synthesis.

HY-137782

Palmitoleoyl-CoA	Biochemical Assay Reagents
Palmitoleoyl coenzyme A lithium salt is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-141474

Glutaryl coenzyme A lithium	Biochemical Assay Reagents
Glutaryl coenzyme A lithium is a Glutaryl coenzyme A derivative. Glutaryl coenzyme A is an important endogenous metabolites. Glutaryl coenzyme A lithium can be used in HMG-CoA or Glutaryl-CoA related experiment.

HY-116037

cis-10-Heptadecenoic acid	Biochemical Assay Reagents
cis-10-Heptadecenoic acid is a cis-fatty acid. cis-10-Heptadecenoic acid synthesizes polyhydroxy-chain alkanoates under the action of 2, 4-dienyl-CoA reductase and Delta3, Delta2-enyl-CoA isomerase.

HY-114294A

DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium	Biochemical Assay Reagents
DL-3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) disodium is a disodium salt compound of HMG-CoA, is a intermediate of terpenes and ketone bodies. DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium also involves in ester metabolism in vivo, as a precursor for cholesterol synthesis, and regulates cholesterol synthesis by coupling LDL receptor.

HY-109591

Oleoyl Coenzyme A	Biochemical Assay Reagents
Oleoyl coenzyme A (Oleoyl-CoA) is a thioester of oleic acid and coenzyme A. Oleoyl coenzyme A has a role as an Escherichia coli metabolite and a mouse metabolite.

HY-134426

DL-β-Hydroxybutyryl coenzyme A lithium	Biochemical Assay Reagents
DL-β-Hydroxybutyryl coenzyme A lithium is an intermediate in the fermentation of butyric acid and the metabolism of lysine and tryptophan, and is produced from β-hydroxybutyric acid by short-chain-CoA synthase.

HY-P2887

Acetate kinase (ACK)	Enzyme
Acetate kinase (ACK) is an enzyme widely distributed in bacteria and archaea. In the presence of ATP and divalent cations, it catalyzes the phosphorylation of acetate and promotes the production of acetyl-CoA. Often used in biochemical research.

HY-125139

omega-3 Arachidonic acid ethyl ester

ω-3 Arachidonic acid ethyl ester; (all-Z)-8,11,14,17-Eicosatetraenoic acid ethyl ester

Biochemical Assay Reagents

omega-3 Arachidonic Acid ethyl ester is a rare polyunsaturated fatty acid found in very small amounts in dietary sources. Omega-3 fatty acids are known to be essential for the growth and development of infants, and they protect against heart disease, blood clots, high blood pressure, and inflammatory and autoimmune diseases. In human platelet membranes, omega-3 arachidonic acid inhibits arachidonyl-CoA synthetase with a Ki of 14 μM. It also inhibits arachidonoyl-CoA synthetase in calf brain extract with an IC50 of approximately 5 μM. Omega-3 ethyl arachidonate is the more lipophilic form of the free acid.

HY-134421

2-Butenoyl coenzyme A lithium	Biochemical Assay Reagents
2-Butenoyl coenzyme A (lithium), an active compound, can be used as a substrate for plasmodium falciparum enyl-ACP reductases and other enyl-CoA reductases. 2-Butenoyl coenzyme A lithium can be used as a substrate analogue to study the kinetics of β-hydroxyacyl-acyl-carrier protein (ACP) dehydratase (FabZ).

Cat. No.	Product Name	Target	Research Area

HY-P2827

*Acetyl-CoA* synthetase** ACS	Peptides	Others
Acetyl-CoA synthetase (ACS) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

Cat. No.	Product Name	Target	Category

HY-N4301

Monensin B	Others	Natural Products Classification of Application Fields Disease Research Fields Other Diseases Source classification Microorganisms
Monensin B is a polyketide produced by Streptomyces cinnamonensis. Fermentations of Streptomyces cinnamonensis produce a mixture of Monensin A and Monensin B in a ratio dependent upon the relative concentrations of ethylmalonyl-CoA and methylmalonyl-CoA.

HY-113410

3-Methylglutaric acid	Endogenous Metabolite	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Endogenous metabolite Disease markers Endocrine diseases Nervous System Disorder Cardiovascular System Disorder
3-Methylglutaric acid, a leucine metabolite, is a conspicuous C6 dicarboxylic organic acid classically associated with two distinct leucine pathway enzyme deficiencies, 3-hydroxy-3-methylglutaryl CoA lyase (HMGCL) and 3-methylglutaconyl CoA hydratase (AUH).

HY-N7392

Acetoacetyl-CoA	Biochemical Assay Reagents	Metabolic Disease Disease Research Fields Classification of Application Fields
Acetoacetyl CoA is the precursor of HMG-CoA in the mevalonate pathway. Acetoacetyl-CoA thiolase catalyzes the reaction to form acetoacetyl-CoA from two acetyl-CoA molecules. Acetoacetyl CoA is essential for cholesterol biosynthesis. Acetoacetyl-CoA is also a intermediate in the biological breakdown and synthesis of fatty acids.

HY-B0430B

(±)-Pantothenic acid (±)-Pantothenate; (±)-Vitamin B5	Others	Endogenous metabolite Disease markers Other disease
(±)-Pantothenic acid ((±)-Pantothenate), a B-vitamin, is an essential vitamin required for the biosynthesis of coenzyme A (CoA) in mammalian cells. Pantothenic acid has protective activity against valproic acid (VPA)-induced neural tube defects (NTD) in CD-1 mice.

HY-N9686

Caffeoyl-CoA

Others Natural Products Source classification Plants Gramineae Secale cereale

Caffeoyl-CoAcould be isolated from leaf tissues of Gramineae with a K_m value of 1.45 μM.

HY-W017522

Adipic acid	Endogenous Metabolite	Ketones, Aldehydes, Acids Structural Classification Cardiovascular System Disorder Disease markers Cancer Endocrine diseases Endogenous metabolite Source classification Metabolic Disease Disease Research Fields Classification of Application Fields
Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism.

HY-116037A

trans-10-Heptadecenoic acid	Others	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source classification
trans-10-Heptadecenoic acid is a trans-fatty acid. trans-10-Heptadecenoic acid synthesizes polyhydroxy-chain alkanoates under the action of 2, 4-dienyl-CoA reductase and Delta3, Delta2-enyl-CoA isomerase. In the absence of 2, 4-dienyl-CoA reductase, trans-10-Heptadecenoic acid is degraded by enyl-CoA hydratase II of the multifunctional enzyme (MFE). trans-10-Heptadecenoic acid leads to massive intracellular carbon outflow through reductase dependent and direct MFE dependent pathways.

HY-113165

Isobutyryl-L-carnitine	Endogenous Metabolite	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Endogenous metabolite
Isobutyryl-L-carnitine is a product of the acyl-CoA dehydrogenases.

HY-N0504

Lovastatin 15+ Cited Publications Mevinolin	HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis	Ketones, Aldehydes, Acids Structural Classification Microorganisms Source classification Disease Research Fields Cancer Classification of Application Fields
Lovastatin is a cell-permeable *HMG-CoA* reductase** inhibitor used to lower cholesterol.

HY-N2923

β-Amyrin acetate	HMG-CoA Reductase (HMGCR) Fungal	Triterpenes Structural Classification Ficus exasperata Vahl Plants Source classification Moraceae
β-Amyrin acetate is a triterpenoid with potent anti-inflammatory, antifungal, anti-diabetic, anti-hyperlipidemic activities. β-Amyrin acetate can inhibit *HMG-CoA* reductase activity by locating in the hydrophobic binding cleft of HMG CoA reductase.

HY-34740

Ethylmalonic acid	Endogenous Metabolite	Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease markers Endocrine diseases Nervous System Disorder Immune System Disorder
Ethylmalonic acid is non-carcinogenic potentially toxic and associated with anorexia nervosa and malonyl-CoA decarboxylase deficiency.

HY-W015300

Suberic acid Octanedioic acid	Endogenous Metabolite	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Endogenous metabolite Disease markers Endocrine diseases Cardiovascular System Disorder
Suberic acid (Octanedioic acid) is found to be associated with carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency.

HY-N7347

(-)-Hydroxycitric acid lactone Garcinia lactone	ATP Citrate Lyase	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants other families
(-)-Hydroxycitric acid lactone (Garcinia lactone) is an anti-obesity agent and a popular weight loss food supplement. (-)-Hydroxycitric acid lactone is a potent inhibitor of ATP-citrate lyase. (-)-Hydroxycitric acid lactone catalyzes the extramitochondrial cleavage of citrate to oxaloacetate and acetyl-CoA, limits the availability of acetyl-CoA units required for fatty acid synthesis.

HY-113408

Tiglyl carnitine 1 Publications Verification	Endogenous Metabolite	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Endogenous metabolite
Tiglyl carnitine is found to be associated with celiac disease and mitochondrial acetoacetyl-CoA thiolase (T2) deficiency.

HY-W015444

2-Hydroxyoctanoic acid	Endogenous Metabolite	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Endogenous metabolite
2-Hydroxyoctanoic acid is a *medium chain acyl-CoA* synthetase inhibitor with a K_i** of 500 μM.

HY-B0165A

Pravastatin sodium 4 Publications Verification CS-514 sodium	HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis	Ketones, Aldehydes, Acids Disease Research Fields Cancer Classification of Application Fields Cardiovascular Disease Source classification Microorganisms
Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC₅₀ of 5.6 μM.

HY-W014787

Decanedioic acid	Endogenous Metabolite	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Endogenous metabolite Disease markers Endocrine diseases Cardiovascular System Disorder
Decanedioic acid, a normal urinary acid, is found to be associated with carnitine-acylcarnitine translocase deficiency and medium chain acyl-CoA dehydrogenase deficiency.

HY-N10234

Phenylpyropene A	Acyltransferase	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Infection Source classification Microorganisms
Phenylpyropene A, a fungal metabolite, is a potent *acyl-CoA: cholesterol acyltransferase (ACAT)* inhibitor with an IC₅₀ of 0.8 μM.

HY-N10224

Terpendole C	Acyltransferase	Alkaloids Indole Alkaloids Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Microorganisms
Terpendole C, produced by Albophoma yamanashiensis, shows potent inhibitory activity against acyl-CoA: cholesterol acyltransferase (ACAT).

HY-N8331

Terpendole I	Acyltransferase Endogenous Metabolite	Alkaloids Indole Alkaloids Terpenoids Diterpenoids Classification of Application Fields Disease Research Fields Cancer Source classification Microorganisms
Terpendole I, a fungal indoloditerpene, is a *ACAT (acyl-CoA: cholesterol acyltransferase)* inhibitor (IC₅₀=145 µM).

HY-Y0068

N-Acetyl-L-phenylalanine 1 Publications Verification N-Acetylphenylalanine	Endogenous Metabolite	Amino acids Other Diseases Disease Research Fields Classification of Application Fields Source classification Microorganisms Endogenous metabolite
N-Acetyl-L-phenylalanine (N-Acetylphenylalanine), the principal acylamino acid in Escherichia coli, is synthesized from L-phenylalanine and acetyl-CoA.

HY-126455

Penicillide Vermixocin A	Acyltransferase	Phenols Monophenols Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Microorganisms
Penicillide (Vermixocin A), isolated from Talaromyces derxii cultivated on rice, shows inhibitory activity against acyl-CoA:cholesterol acyltransferase (ACAT).

HY-N0504R

Lovastatin (Standard) Mevinolin (Standard)	HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis	Structural Classification Ketones, Aldehydes, Acids
Lovastatin (Standard) is the analytical standard of Lovastatin. This product is intended for research and analytical applications. Lovastatin is a cell-permeable *HMG-CoA* reductase** inhibitor used to lower cholesterol.

HY-112790

Adenosylcobalamin Coenzyme B12; Cobamamide; AdoCbl	Endogenous Metabolite	Natural Products Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Endogenous metabolite
Adenosylcobalamin (Coenzyme B12;Cobamamide;AdoCbl) is an active form of Vitamin B₁₂ which is a cofactor for methylmalonyl CoA mutase

HY-113166

Dodecanoylcarnitine	Endogenous Metabolite	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Endogenous metabolite Disease markers Endocrine diseases Immune System Disorder
Dodecanoylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I/II deficiency, and is also associated with celiac disease.

HY-N2924

β-Amyrin palmitate	HMG-CoA Reductase (HMGCR)	Terpenoids Triterpenes Classification of Application Fields Disease Research Fields Endocrinology Source classification Plants other families
β-Amyrin palmitate shows HMG-CoA* reductase* inhibition. And β-Amyrin palmitate has anti-diabetes mellitus activity.

HY-N6739

Beauvericin	Acyltransferase	Structural Classification Antibiotics Antibacterial Disease Research Macrolide Antibiotics Microorganisms Source classification Disease Research Fields Classification of Application Fields Cardiovascular Disease
Beauvericin is a Fusarium mycotoxin. Beauvericin inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC₅₀ of 3 μM in an enzyme assay using rat liver microsomes.

HY-N9524

Ilexoside XLVIII	Acyltransferase	Triterpenes Terpenoids Structural Classification Ilex latifolia Thunb. Aquifoliaceae Plants Source classification Metabolic Disease Disease Research Fields Classification of Application Fields
Ilexoside XLVIII is an acyl CoA cholesteryl acyl transferase (ACAT) inhibitor. Ilexoside XLVIII is a triterpene saponin isolated from an aqueous extract of the leaves of Ilex kudincha.

HY-N6702

Enniatin A	Acyltransferase	Structural Classification Antibiotics Antibacterial Disease Research Macrolide Antibiotics Microorganisms Source classification Disease Research Fields Classification of Application Fields Cardiovascular Disease
Enniatin A is a Fusarium mycotoxin. Enniatin A inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC₅₀ of 22 μM in an enzyme assay using rat liver microsomes.

HY-B1189

Meglutol Dicrotalic acid; 3-Hydroxy-3-methylglutaric acid	HMG-CoA Reductase (HMGCR) Autophagy Endogenous Metabolite	Ketones, Aldehydes, Acids Disease Research Fields Classification of Application Fields Cardiovascular Disease Source classification Endogenous metabolite
Meglutol is an antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids, and inhibits the activity of hydroxymethylglutarryl CoA reductases, which is the rate limiting enzyme in the biosynthesis of cholesterol.

HY-Y1125

6-Methyluracil Pseudothymine	Endogenous Metabolite	Natural Products Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Endogenous metabolite
6-Methyluracil (Pseudothymine), a metabolite of Uracil, can be used as an indicator of acetoacetyl-CoA (AACoA) accumulation. 6-Methyluracil exhibits antiradiation effect in vivo.

HY-B0165AR

Pravastatin sodium (Standard) CS-514 sodium (Standard)	HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis	Structural Classification Ketones, Aldehydes, Acids
Pravastatin (sodium) (Standard) is the analytical standard of Pravastatin (sodium). This product is intended for research and analytical applications. Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC₅₀ of 5.6 μM.

HY-W009993

3,4-Methylenedioxycinnamic acid	Others	Ketones, Aldehydes, Acids Source classification Plants Piperaceae Piper nigrum Linn.
3,4-Methylenedioxycinnamic acid is an inhibitor of the *phenylpropanoid enzyme 4-hydroxycinnamoyl-CoA* ligase**. 3,4-Methylenedioxycinnamic acid increases the formation of soluble phenolics in particular of vanillic acid.

HY-N11637

Ganoderenic acid K	HMG-CoA Reductase (HMGCR)	Triterpenes Structural Classification Terpenoids Microorganisms Source classification
Ganoderenic acid K is a natural product, that can be isolated from fruiting bodies of Ganoderma lucidum. Ganoderenic acid K shows strong inhibitory activity against *HMG-CoA* reductase (HMGCR) with IC₅₀** of 16.5 μM.

HY-N10076

Ganomycin I	HMG-CoA Reductase (HMGCR) Glucosidase HIV Protease	Structural Classification Phenols Polyphenols Microorganisms Source classification
Ganomycin I is a dual inhibitor of α-Glucosidase and *HMG-CoA* reductase. Ganomycin I can also inhibits HIV protease**. Ganomycin I exhibits anti-diabetic and anti-osteoclastogenesis effects.

HY-B0430

D-Pantothenic acid 2 Publications Verification Pantothenate; Vitamin B5	Endogenous Metabolite	Ketones, Aldehydes, Acids Structural Classification other families Plants Animals Source classification Other Diseases Disease Research Fields Classification of Application Fields
D-Pantothenic acid (Pantothenate) is an essential trace nutrient that functions as the obligate precursor of coenzyme A (CoA). D-Pantothenic acid plays key roles in myriad biological processes, including many that regulate carbohydrate, lipid, protein, and nucleic acid metabolism.

HY-125130

Hesperetin 7-O-glucoside	HMG-CoA Reductase (HMGCR) Bacterial	Phenols Polyphenols Flavonones Structural Classification Flavonoids Umbelliferae Ajuga reptans L. Plants Source classification Metabolic Disease Disease Research Fields Classification of Application Fields
Hesperetin 7-O-glucoside is produced by the enzymatic conversion of Hesperidin. Hesperetin 7-O-glucoside is a potent *human HMG-CoA* reductase inhibitor and also effectively inhibits the growth of Helicobacter pylori**. Antihypertensive effect.

HY-W020033

Lanosterol 1 Publications Verification	Endogenous Metabolite	Triterpenes Terpenoids Structural Classification Endogenous metabolite Source classification
Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol suppresses the aggregation and cytotoxicity of misfolded proteins linked with neurodegenerative diseases.

HY-127143

Sterculic acid	Stearoyl-CoA Desaturase (SCD)	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants Sterculiaceae Sterculia foetida Linn.
Sterculic acid is a stearoyl-CoA desaturase-1 (SCD1) inhibitor. Sterculic acid specifically inhibits the delta-9 desaturase (Δ9D) activity with an IC₅₀ value of 0.9 μM.

HY-N6706

Enniatin complex	Bacterial Acyltransferase Apoptosis	Structural Classification Antibiotics Anticancer Antibacterial Disease Research Other Antibiotics Microorganisms Source classification Infection Disease Research Fields Classification of Application Fields
Enniatin complex is a mixture of cyclohexadepsipeptides isolated largely from Fusarium species of fungi, and has ionophoric, antibiotic, and in vitro hypolipidaemic properties. Enniatin complex inhibits enzymes like acyl-CoA: cholesterol acyl transferase and induces apoptosis in several cancer lines .

HY-113342

7-Ketocholesterol	Endogenous Metabolite	Triterpenes Structural Classification Terpenoids
7-Ketocholesterol, toxic oxysterol, inhibits the rate-limiting step in bile acid biosynthesis cholesterol 7 alpha-hydroxylase, as well as strongly inhibiting *HMG-CoA* reductase** (the rate-limiting enzyme in cholesterol biosynthesis). 7-Ketocholesterol induces cell apoptosis.

HY-N6807

Elemicin	Stearoyl-CoA Desaturase (SCD) Influenza Virus	Phenylpropanoids Simple Phenylpropanols Infection Disease Research Fields Classification of Application Fields Source classification Plants Aristolochiaceae Asarum sieboldii Miq.
Elemicin is a alkenylbenzene widely distributed in many herbs and spices. Elemicin inhibits *Stearoyl-CoA* Desaturase 1 (SCD1)** by metabolic activation. Elemicin is one of the main components in aromatic food and has antimicrobial, antioxidant, and antiviral activities. Elemicin possesses genotoxicity and carcinogenicity.

HY-W050031

(S)-3-Hydroxybutanoic acid 1 Publications Verification (S)-β-Hydroxybutanoic acid; L-(+)-3-Hydroxybutyric acid; L-β-Hydroxybutyric acid	Endogenous Metabolite	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Other Diseases Source classification Endogenous metabolite
(S)-3-Hydroxybutanoic acid is a normal human metabolite, that has been found elevated in geriatric patients remitting from depression. In humans, 3-Hydroxybutyric acid is synthesized in the liver from acetyl-CoA, and can be used as an energy source by the brain when blood glucose is low.

HY-N3806

Enniatin B	Acyltransferase ERK	Alkaloids Infection Disease Research Fields Classification of Application Fields Cardiovascular Disease Source classification Microorganisms
Enniatin B is a Fusarium mycotoxin. Enniatin B inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC₅₀ of 113 μM in an enzyme assay using rat liver microsomes. Enniatins B decreases the activation of ERK (p44/p42).

HY-N6707

Triacsin C 1 Publications Verification WS 1228A; FR 900190	Parasite	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Infection Source classification Microorganisms
Triacsin C (WS 1228A), a natural intracellular long-chain acyl-CoA synthetases (ACSL) inhibitor, is from Streptomyces aureofaciens. Triacsin C inhibits TAG accumulation into lipid droplets (LD) by suppressing ACSL activity. Triacsin C is found to be highly effective against rotavirus replication.

HY-119695A

Simvastatin acid ammonium Tenivastatin ammonium	HMG-CoA Reductase (HMGCR) Reactive Oxygen Species	Ketones, Aldehydes, Acids Structural Classification Endogenous metabolite Source classification Disease Research Fields Classification of Application Fields Cardiovascular Disease
Simvastatin acid (Tenivastatin) ammonium is a potent *HMG-CoA* reductase (HMGCR) inhibitor. Simvastatin acid ammonium reduces Indoxyl sulfate-mediated reactive oxygen species** (ROS) production in human cardiomyocytes. Simvastatin acid ammonium can also modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene.

HY-B0399

L-Carnitine 5+ Cited Publications (R)-Carnitine; Levocarnitine	Endogenous Metabolite	Structural Classification Natural Products Nervous System Disorder Immune System Disorder Disease markers Cancer Endocrine diseases Endogenous metabolite Source classification Neurological Disease Disease Research Fields
L-Carnitine ((R)-Carnitine), a highly polar, small zwitterion, is an essential co-factor for the mitochondrial β-oxidation pathway. L-Carnitine functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by β-oxidation. L-Carnitine is an antioxidant. L-Carnitine can ameliorate metabolic imbalances in many inborn errors of metabolism.

HY-B2246

L-Carnitine hydrochloride 5+ Cited Publications (R)-Carnitine hydrochloride; Levocarnitine hydrochloride	Endogenous Metabolite	Ketones, Aldehydes, Acids Structural Classification Endogenous metabolite Source classification Metabolic Disease Disease Research Fields Classification of Application Fields
L-Carnitine hydrochloride ((R)-Carnitine hydrochloride), a highly polar, small zwitterion, is an essential co-factor for the mitochondrial β-oxidation pathway. L-Carnitine hydrochloride functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by β-oxidation. L-Carnitine hydrochloride is an antioxidant. L-Carnitine hydrochloride can ameliorate metabolic imbalances in many inborn errors of metabolism.

HY-15142

Doxorubicin hydrochloride Maximum Cited Publications 318 Publications Verification Hydroxydaunorubicin hydrochloride	Topoisomerase ADC Cytotoxin AMPK Autophagy Apoptosis HIV HBV Mitophagy Antibiotic Bacterial	Quinones Anthraquinones Structural Classification Microorganisms Source classification Infection Disease Research Fields Classification of Application Fields
Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC₅₀s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy.

HY-17408

Mevastatin 5+ Cited Publications Compactin; ML236B	HMG-CoA Reductase (HMGCR) Bacterial Autophagy Apoptosis Antibiotic	Structural Classification Natural Products Microorganisms Source classification Neurological Disease Infection Metabolic Disease Disease Research Fields Classification of Application Fields Cardiovascular Disease
Mevastatin (Compactin) is a first *HMG-CoA* reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis**, arrests cancer cells in G₀/G₁ phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment.

HY-15142A

Doxorubicin Hydroxydaunorubicin	ADC Cytotoxin Antibiotic Bacterial Topoisomerase AMPK HIV Autophagy Mitophagy Apoptosis HBV	Quinones Anthraquinones Phenols Polyphenols Structural Classification Microorganisms Source classification Infection Disease Research Fields Classification of Application Fields
Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin inhibits topoisomerase II with an IC₅₀ of 2.67 μM, thus stopping DNA replication. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy. Doxorubicin inhibits human DNA topoisomerase I with an IC₅₀ of 0.8 μM.

HY-N3807

Enniatin B1	Acyltransferase ERK NF-κB	Alkaloids Classification of Application Fields Disease Research Fields Cardiovascular Disease Infection Source classification Microorganisms
Enniatin B1 is a Fusarium mycotoxin. Enniatin B1 inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC₅₀ of 73 μM in an enzyme assay using rat liver microsomes. Enniatin B1 crosss the blood-brain barrier. Enniatin B1 decreases the activation of ERK (p44/p42). Enniatin B1 inhibits moderately TNF-α-induced NF-κB activation.

Species:	Human (19) Mouse (5) Rat (1) Staphylococcus aureus (1)
Tag:	His (24) SUMO (1) Tag Free (1) Myc (2) GST (1) Trx (1)
Source:	HEK293 (3) P. pastoris (3) Sf9 insect cells (6) E. coli (14)

Cat. No.	Product Name	Species	Source

HY-P71041

ACAT2 Protein, Human (Trx-His) Acetyl-coa acetyltransferase cytosolic; Acetyl-coa transferase-like protein; Cytosolic acetoacetyl-coa thiolase; ACTL; ACAT2	Human	E. coli
ACAT2, Human (Trx-His) is the major ACAT enzyme in human hepatocytes. ACAT2, Human is an important regulator of susceptibility to the development of atherosclerosis.

HY-P72228

HMGCR Protein, Human (His) 3 hydroxy 3 methylglutaryl coa reductase; 3 hydroxy 3 methylglutaryl Coenzyme A reductase; 3 hydroxymethylglutaryl coa reductase; 3-hydroxy-3-methylglutaryl coa reductase NADPH; ; 3-hydroxy-3-methylglutaryl-coenzyme A reductase; 3H3M; HMDH_HUMAN; HMG coa reductase; HMG coaR; HMG-coa reductase; Hmgcr; Hydroxymethylglutaryl coa reductase; LDLCQ3; MGC103269; Red	Human	E. coli

HY-P701332

ACAT2 Protein, Human (His, Myc)

Acetyl-coa acetyltransferase cytosolic; Acetyl-coa transferase-like protein; Cytosolic acetoacetyl-coa thiolase; ACTL; ACAT2
Human E. coli
HY-P70895

MCEE Protein, Human (HEK293, His)

Methylmalonyl-coa epimerase; mitochondrial; DL-methylmalonyl-coa racemase
Human HEK293

HY-P71642

*Acetyl-CoA* synthetase 1/AceCS Protein, Mouse (His)** Acss2; Acas2; Acecs1Acetyl-coenzyme A synthetase; cytoplasmic; EC 6.2.1.1; Acetate--coa ligase; Acetyl-coa synthetase; ACS; AceCS; Acetyl-coa synthetase 1; AceCS1	Mouse	E. coli
Acetyl-CoA synthetase 1/AceCS Protein, Mouse (His) is an enzyme that converts acetate to acetyl-CoA, which supplies acetyl-CoA for tumor cells by capturing acetate as a carbon source under stressed conditions.

HY-P71851

ACSS1 Protein, Human (P.pastoris, His) ACAS2L; Acetate coa ligase 2; Acetate--coa ligase 2	Human	P. pastoris
ACSS1 Protein, Human (P.pastoris, His) is a mitochondrial matrix enzyme that is expressed in heart, skeletal muscle and brown adipose tissue. ACSS1 Protein, Human is involved in acetate-mediated epigenetic regulation.

HY-P70888

GCDH Protein, Human (His)

Glutaryl-coa Dehydrogenase Mitochondrial; GCD; GCDH
Human E. coli

HY-P71471

HADHB Protein, Human (GST) 3-ketoacyl-coa thiolase; Acetyl coa acyltransferase; Acetyl-coa acyltransferase; Beta ketothiolase; Beta-ketothiolase; ECHB; ECHB_HUMAN; HADH; Hadhb; beta subunit; Hydroxyacyl Coenzyme A (coa) dehydrogenase beta subunit; MGC87480; MSTP 029; MSTP029; MTPB; TP beta; TP-beta; TPbeta; Trifunctional enzyme subunit beta; Trifunct	Human	E. coli

HY-P73856

IVD Protein, Mouse (sf9, His)

Isovaleryl-coa dehydrogenase, mitochondrial; IVD
Mouse Sf9 insect cells
HY-P73857

IVD Protein, Human (sf9, His)

Isovaleryl-coa dehydrogenase, mitochondrial; IVD
Human Sf9 insect cells
HY-P76544

PHYH Protein, Human

Phytanoyl-coa dioxygenase, peroxisomal; Phytanic acid oxidase; PhyH; PAHX
Human E. coli
HY-P74435

AACS Protein, Human (sf9, His)

Acetoacetyl-coa synthetase; AACS; ACSF1
Human Sf9 insect cells
HY-P75543

ACAT2 Protein, Rat (His)

Acetyl-coa acetyltransferase cytosolic; ACTL; ACAT2
Rat E. coli
HY-P76357

GCDH Protein, Human (sf9, His)

Glutaryl-coa Dehydrogenase Mitochondrial; GCD; GCDH
Human Sf9 insect cells
HY-P70059

ECH1 Protein, Human (His)

rHuDelta(3,5)-Delta(2,4)-dienoyl-coa isomerase, mitochondrial/ECH1, His; Delta(3,5)-Delta(2,4)-dienoyl-coa isomerase; mitochondrial; ECH1;
Human E. coli
HY-P76843

COASY Protein, Human (His)

Bifunctional coenzyme A synthase; coa synthase; NBP; POV-2; PPAT; DPCK
Human E. coli
HY-P72167

DBI Protein, Mouse (His-Myc)

DbiAcyl-coa-binding protein; ACBP; Diazepam-binding inhibitor; DBI; Endozepine; EP
Mouse E. coli
HY-P76709

ACBD7 Protein, Human (His)

Acyl-coa-binding domain-containing protein 7; ACBD7
Human E. coli

HY-P72166

DBI Protein, Human (103a.a, His) ACBD1; ACBP; ACBP_HUMAN; Acyl coa binding domain containing 1; Acyl coa binding protein; Acyl Coenzyme A binding domain containing 1; Acyl coenzyme A binding protein; Acyl-coa-binding protein; CCK RP; CCKRP; Cholecystokinin releasing peptide trypsin sensitive; DBI; Diazepam-binding inhibitor; Endozepine; EP; GABA receptor modulator; MGC70414	Human	E. coli

HY-P76708

ACBD6 Protein, Human (sf9, His)

Acyl-coa-binding domain-containing protein 6; ACBD6
Human Sf9 insect cells
HY-P75558

ACAA1 Protein, Human (sf9, His)

3-ketoacyl-coa thiolase, peroxisomal; Beta-ketothiolase; ACAA1; ACAA; PTHIO
Human Sf9 insect cells

HY-P71828

MCT/SACOL1244 Protein, S. aureus (P.pastoris, His) 1 Publications Verification fabD; SACOL1244Malonyl coa-acyl carrier protein transacylase; MCT; EC 2.3.1.39	Staphylococcus aureus	P. pastoris

HY-P77206

SLC27A4/FATP4 Protein, Human (HEK293, His)

Long-chain fatty acid transport protein 4; Arachidonate--coa ligase; ACSVL4
Human HEK293
HY-P700627

DBI Protein, Mouse (P. pastoris, His)

Dbi; diazepam binding inhibitor; EP; Acbp; ACBD1; endozepine; acyl-coa-binding protein; diazepam binding inhibitor, splice form 1b
Mouse P. pastoris

HY-P70140

MECR Protein, Human (HEK293, His) rHuEnoyl-[acyl-carrier-protein] reductase, mitochondrial/MECR, His; Trans-2-Enoyl-coa Reductase Mitochondrial; Nuclear Receptor-Binding Factor 1; HsNrbf-1NRBF-1; MECR; NBRF1	Human	HEK293

HY-P71563

HCDH Protein, Mouse (His-SUMO) Hadh; Hadhsc; Mschad; Schad; Hydroxyacyl-coenzyme A dehydrogenase; mitochondrial; HCDH; EC 1.1.1.35; Medium and short-chain L-3-hydroxyacyl-coenzyme A dehydrogenase; Short-chain 3-hydroxyacyl-coa dehydrogenase	Mouse	E. coli

Cat. No.	Product Name

HY-W017522S

Adipic acid-d10
Adipic acid-d₁₀ is the deuterium labeled Adipic acid[1]. Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism[2].

HY-W017522S3

Adipic acid-13C
Adipic acid-¹³C is the ¹³C labeled Adipic acid[1]. Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism[2].

HY-W017522S2

Adipic acid-d4
Adipic acid-d₄ is the deuterium labeled Adipic acid[1]. Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism[2].

HY-W017522S1

Adipic acid-13C6
Adipic acid-¹³C₆ is the ¹³C labeled Adipic acid[1]. Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism[2].

HY-W017522S4

Adipic acid-d8
Adipic acid-d₈ is the deuterium labeled Adipic acid[1]. Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism[2].

HY-W017522S5

Adipic acid-d4-1
Adipic acid-d₄-1 is the deuterium labeled Adipic acid[1]. Adipic acid is found to be associated with HMG-CoA lyase deficiency, carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency, and medium Chain acyl-CoA dehydrogenase deficiency, which are inborn errors of metabolism[2].

HY-B0144AS

Pitavastatin D4

Pitavastatin-d₄ is deuterium labeled Pitavastatin. Pitavastatin is a potent HMG-CoA reductase inhibitor.

HY-B0144AS1

Pitavastatin-d5 sodium
Pitavastatin-d₅ (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.

HY-N0504S1

Lovastatin-d9

Lovastatin-d₉ is the deuterium labeled Lovastatin. Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.
HY-N0504S2

Lovastatin-d3

Lovastatin-d₃ is deuterium labeled Lovastatin. Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.

HY-113165AS

Isobutyryl-L-carnitine-d3 chloride
Isobutyryl-L-carnitine-d₃ (chloride) is the deuterium labeled Isobutyryl-L-carnitine chloride. Isobutyryl-L-carnitine chloride is a product of the acyl-CoA dehydrogenases[1].

HY-113410S

3-Methylglutaric acid-d4
3-Methylglutaric acid-d₄ is the deuterium labeled 3-Methylglutaric acid[1]. 3-Methylglutaric acid, a leucine metabolite, is a conspicuous C6 dicarboxylic organic acid classically associated with two distinct leucine pathway enzyme deficiencies, 3-hydroxy-3-methylglutaryl CoA lyase (HMGCL) and 3-methylglutaconyl CoA hydratase (AUH)[2][3].

HY-14664AS

Fluvastatin-d6 sodium
Fluvastatin-d₆ (sodium) is deuterium labeled Fluvastatin sodium. Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM.

HY-17502S

Simvastatin-d11

Simvastatin-d₁₁ is the deuterium labeled Simvastatin. Simvastatin (MK 733) is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM[1][2].

HY-34740S

Ethylmalonic acid-d3
Ethylmalonic acid-d₃ is the deuterium labeled Ethylmalonic acid. Ethylmalonic acid is non-carcinogenic potentially toxic and associated with anorexia nervosa and malonyl-CoA decarboxylase deficiency.

HY-34740S1

Ethylmalonic acid-d5
Ethylmalonic acid-d₅ is the deuterium labeled Ethylmalonic acid. Ethylmalonic acid is non-carcinogenic potentially toxic and associated with anorexia nervosa and malonyl-CoA decarboxylase deficiency.

HY-B0144S

Pitavastatin-d4 hemicalcium

Pitavastatin-d₄ (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].

HY-17502S1

Simvastatin-d3

Simvastatin-d₃ is the deuterium labeled Simvastatin[1]. Simvastatin (MK 733) is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM[2].

HY-123672S

Lovastatin-d3 hydroxy acid sodium
Lovastatin-d₃ hydroxy acid (sodium) is the deuterium labeled Lovastatin hydroxy acid sodium. Lovastatin hydroxy acid sodium (Mevinolinic acid sodium) is a highly potent inhibitor of HMG-CoA reductase with a Ki of 0.6 nM[1].

HY-W015300S

Suberic acid-d4
Suberic acid-d₄ is the deuterium labeled Suberic acid[1]. Suberic acid (Octanedioic acid) is found to be associated with carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency[2].

HY-B0165CS

Pravastatin-d3 sodium salt
Pravastatin-d₃ (sodium) is the deuterium labeled Pravastatin sodium salt. Pravastatin (CS-514) sodium salt is a competitive HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM[1][2].

HY-W015300S1

Suberic acid-d12
Suberic acid-d₁₂ is the deuterium labeled Suberic acid[1]. Suberic acid (Octanedioic acid) is found to be associated with carnitine-acylcarnitine translocase deficiency, malonyl-Coa decarboxylase deficiency[2].

HY-B0165AS

Pravastatin-13C,d3 sodium
Pravastatin-¹³C,d₃ (sodium) is the ¹³C- and deuterium labeled Pravastatin (sodium). Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.

HY-W020033S

Lanosterol-d6
Lanosterol-d₆ is deuterium labeled Lanosterol. Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol s

HY-W014787S

Decanedioic acid-d4
Decanedioic acid-d₄ is the deuterium labeled Decanedioic acid[1]. Decanedioic acid, a normal urinary acid, is found to be associated with carnitine-acylcarnitine translocase deficiency and medium chain acyl-CoA dehydrogenase deficiency[2].

HY-W014787S1

Decanedioic acid-d16
Decanedioic acid-d₁₆ is the deuterium labeled Decanedioic acid[1]. Decanedioic acid, a normal urinary acid, is found to be associated with carnitine-acylcarnitine translocase deficiency and medium chain acyl-CoA dehydrogenase deficiency[2].

HY-134423S

Stearoyl coenzyme A-13C18 lithium
Stearoyl coenzyme A-¹³C₁₈ (lithium) is the ¹³C labeled Stearoyl coenzyme A lithium[1]. Stearoyl coenzyme A (Stearoyl-CoA) lithium is an active compound that can be used as a substrate for the determination of stearoyl-Coenzyme desaturase in microsomes[2].

HY-B1189S

Meglutol-d3
Meglutol-d₃ is the deuterium labeled Meglutol[1]. Meglutol is an antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids, and inhibits the activity of hydroxymethylglutarryl CoA reductases, which is the rate limiting enzyme in the biosynthesis of cholesterol.

HY-101873S

Atorvastatin lactone-d5
Atorvastatin lactone-d₅ is a deuterated form of Atorvastatin lactone (HY-101873). Atorvastatin lactone is a proagent form of atorvastatin. Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor[1].

HY-109591S

Oleoyl coenzyme A-13C18 lithium
Oleoyl coenzyme A-¹³C₁₈ (lithium) is the ¹³C labeled Oleoyl Coenzyme A lithium[1]. Oleoyl coenzyme A (Oleoyl-CoA) is a thioester of oleic acid and coenzyme A. Oleoyl coenzyme A has a role as an Escherichia coli metabolite and a mouse metabolite[2][3].

HY-136346S

Ortho-hydroxy atorvastatin lactone-d5
Ortho-hydroxy atorvastatin lactone-d₅ is deuterium labeled 2-Hydroxy atorvastatin lactone. 2-Hydroxy atorvastatin lactone is a metabolite of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids[1][2].

HY-113067S

Phytanic acid-d3
Phytanic acid-d₃ is the deuterium labeled Phytanic acid[1]. Phytanic acid is an endogenous metabolite present in Blood that can be used for the research of Zellweger Syndrome, Alpha Methylacyl CoA Racemase Deficiency, Rhizomelic Chondrodysplasia Punctata and Infantile Refsum Disease[2][3][4][5][6].

HY-B0589S1

Atorvastatin-d5 sodium
Atorvastatin-d₅ (sodium) is the deuterium labeled Atorvastatin sodium. Atorvastatin sodium is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin sodium inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3][4].

HY-B0589S

Atorvastatin-d5 hemicalcium
Atorvastatin-d₅ (hemicalcium) is the deuterium labeled Atorvastatin. Atorvastatin hemicalcium is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3].

HY-B0430S

Pantothenic acid-13C3,15N hemicalcium
Pantothenic acid-¹³C₃,¹⁵N (hemicalcium) is the ¹³C-labeled and ¹⁵N-labeled D-Pantothenic acid. D-Pantothenic acid is an essential trace nutrient that functions as the obligate precursor of coenzyme A (CoA). D-Pantothenic acid plays key roles in myriad biological processes, including many that regulate carbohydrate, lipid, protein, and nucleic acid metabolism[1].

HY-17504AS

Rosuvastatin D3
Rosuvastatin-d₃ is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM[1]. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals[2].

HY-14664DS

(3S,5R)-Fluvastatin-d6
(3S,5R)-Fluvastatin-d₆ is the deuterium labeled (3S,5R)-Fluvastatin sodium. Fluvastatin is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway[1].

HY-14664CS

(3S,5R)-Fluvastatin-d6 sodium
(3S,5R)-Fluvastatin-d₆ (sodium) is the deuterium labeled (3S,5R)-Fluvastatin sodium. Fluvastatin is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway[1].

HY-B2246S

L-Carnitine-d9 chloride

L-Carnitine-d₉ (chloride)e is the deuterium labeled L-Carnitine chloride. L-Carnitine chloride, a highly polar, small zwitterion, is an essential co-factor for the mitochondrial β-oxidation pathway. L-Carnitine chloride functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by β-oxidation. L-Carnitine chloride is an antioxidant. L-Carnitine chloride can ameliorate metabolic imbalances in many inborn errors of metabolism[1][2][3].

HY-B0968S

Trimetazidine-d8 dihydrochloride

Trimetazidine-d₈ (dihydrochloride) is the deuterium labeled Trimetazidine dihydrochloride. Trimetazidine dihydrochloride is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine dihydrochloride is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine dihydrochloride triggers autophagy. Trimetazidine dihydrochloride is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor[1][2][3][4].

HY-B0399S

L-Carnitine-d9

L-Carnitine-d₉ is the deuterium labeled L-Carnitine. L-Carnitine (Levocarnitine) is an endogenous molecule involved in fatty acid metabolism, biosynthesized within the human body using amino acids: L-lysine and L-methionine, as substrates. L-Carnitine functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by β-oxidation. L-carnitine can ameliorate metabolic imbalances in many inborn errors of metabolism[1][2].

Cat. No.	Product Name	Application	Reactivity

HY-P80483

*Acetyl CoA* synthetaseAntibody**	WB, ICC/IF	Human, Mouse, Rat
Acetyl CoA synthetaseAntibody is a non-conjugated and Rabbit origined monoclonal antibody about 79 kDa, targeting to Acetyl CoA synthetase. It can be used for WB,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.

HY-P80482

*Acetyl CoA* Carboxylase 1 (ACC1) Antibody**	WB, IHC-P	Human, Mouse
Acetyl CoA Carboxylase 1 (ACC1) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 266 kDa, targeting to Acetyl CoA Carboxylase 1(ACC1). It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse.

HY-P80541

AMPK alpha Antibody PRKAA2; AMPK; AMPK2; 5'-AMP-activated protein kinase catalytic subunit alpha-2; AMPK subunit alpha-2; Acetyl-coa carboxylase kinase; ACACA kinase; Hydroxymethylglutaryl-coa reductase kinase; HMGCR kinase	WB, IP	Human
AMPK alpha Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 62 kDa, targeting to AMPK alpha. It can be used for WB,IP assays with tag free, in the background of Human .

HY-P80540

AMPK alpha 2 Antibody (YA623) PRKAA2; AMPK; AMPK2; 5'-AMP-activated protein kinase catalytic subunit alpha-2; AMPK subunit alpha-2; Acetyl-coa carboxylase kinase; ACACA kinase; Hydroxymethylglutaryl-coa reductase kinase; HMGCR kinase	WB, IP	Human, Rat
AMPK alpha 2 Antibody (YA623) is a non-conjugated and Rabbit origined monoclonal antibody about 62 kDa, targeting to AMPK alpha 2. It can be used for WB,IP assays with tag free, in the background of Human, Rat.

HY-P80791

Phospho-AMPK alpha 2 (Thr172) Antibody PRKAA2; AMPK; AMPK2; 5'-AMP-activated protein kinase catalytic subunit alpha-2; AMPK subunit alpha-2; Acetyl-coa carboxylase kinase; ACACA kinase; Hydroxymethylglutaryl-coa reductase kinase; HMGCR kinase	WB	Human, Mouse, Rat
Phospho-AMPK alpha 2 (Thr172) Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 62 kDa, targeting to Phospho-AMPK alpha 2 (Thr172). It can be used for WB assays with tag free, in the background of Human, Mouse, Rat.

HY-P80539

AMPK alpha 1 Antibody PRKAA1; AMPK1; 5'-AMP-activated protein kinase catalytic subunit alpha-1; AMPK subunit alpha-1; Acetyl-coa carboxylase kinase; ACACA kinase; Hydroxymethylglutaryl-coa reductase kinase; HMGCR kinase; Tau-protein kinase PRKAA1	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
AMPK alpha 1 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 64 kDa, targeting to AMPK alpha 1. It can be used for WB,IHC-P,ICC/IF,IP,FC assays with tag free, in the background of Human, Mouse, Rat.

HY-P80790

Phospho-AMPK alpha 1 (Ser496) Antibody PRKAA1; AMPK1; 5'-AMP-activated protein kinase catalytic subunit alpha-1; AMPK subunit alpha-1; Acetyl-coa carboxylase kinase; ACACA kinase; Hydroxymethylglutaryl-coa reductase kinase; HMGCR kinase; Tau-protein kinase PRKAA1	WB, IHC-P, ICC/IF	Human, Mouse, Rat
Phospho-AMPK alpha 1 (Ser496) Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 64 kDa, targeting to Phospho-AMPK alpha 1 (Ser496). It can be used for WB,IHC-P,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.

HY-P80787

Phospho-Acetyl Coenzyme A Carboxylase (Ser79) Antibody ACACA; ACAC; ACC1; ACCA; Acetyl-coa carboxylase 1; ACC1; ACC-alpha	WB	Human
Phospho-Acetyl Coenzyme A Carboxylase (Ser79) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 266 kDa, targeting to Phospho-Acetyl Coenzyme A Carboxylase (Ser79). It can be used for WB assays with tag free, in the background of Human.

Acertyl coa carboxilase Inhibitors

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products